var title_f1_3_1072="2D TTE Short axis pleural effusion";
var content_f1_3_1072=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Two-dimensional transthoracic echocardiogram (2D TTE) from the parasternal short axis position showing a pleural effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 206px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The short axis view shows that there is large posteromedial space (arrow) behind the heart. Although superficially resembling a pericardial effusion, its sheer size, unaccompanied by any anterior collection, typifies large pleural effusion. Careful inspection reveals a small posterior pericardial effusion (x).",
"    <div class=\"footnotes\">",
"     LV: left ventricle; RV: right ventricle; A: anterior; P: posterior; R: right; L: left.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_3_1072=[""].join("\n");
var outline_f1_3_1072=null;
var title_f1_3_1073="World recs alcohol consump";
var content_f1_3_1073=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Worldwide recommendations on alcohol consumption",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Country",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Authority",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Standard unit",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Men",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Advice",
"       </td>",
"       <td class=\"subtitle2\">",
"        Max, g/day",
"       </td>",
"       <td class=\"subtitle2\">",
"        Max, g/wk",
"       </td>",
"       <td class=\"subtitle2\">",
"        Advice",
"       </td>",
"       <td class=\"subtitle2\">",
"        Max, g/day",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Max, g/wk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"10\">",
"        Australia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <em>",
"         National Health and Medical Research Council",
"        </em>",
"       </td>",
"       <td>",
"        10 g",
"       </td>",
"       <td>",
"        For a healthy man, four standard drinks per day with two alcohol-free days per week is regarded as low risk",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        For a healthy woman, two standard drinks per day with two alcohol-free days per week is regarded as low risk",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td colspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"10\">",
"        Austria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"6\">",
"        <em>",
"         Bundesministerium f&uuml;r Gesundheit und Konsumentenschutz",
"        </em>",
"       </td>",
"       <td rowspan=\"6\">",
"        See right",
"       </td>",
"       <td class=\"subtitle2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"6\">",
"        Standard drinks per week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Definition",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Men",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Low risk",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        Up to 21",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"4\">",
"        Up to 14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Moderate risk",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        21-50",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"4\">",
"        15-35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        High risk",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        Over 50",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"4\">",
"        Over 35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\" colspan=\"7\">",
"        Trinkeinheiten - standard drinks - are defined as 125 ml of wine; 300 ml of beer; or 20 ml of spirits. This equates to approximately 12g of beer or wine; or 6 g of spirits.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"10\">",
"        Canada",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        <em>",
"         Committee of Health and Welfare",
"        </em>",
"       </td>",
"       <td>",
"        13.5 g*",
"       </td>",
"       <td>",
"        No more than seven drinks per week",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        94.5*",
"       </td>",
"       <td>",
"        No more than seven drinks per week",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td colspan=\"2\">",
"        94.5*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        <em>",
"         Addiction Research Foundation (endorsed by Royal College of Physicians and Surgeons of Canada, Canadian Medical Association and others)",
"        </em>",
"       </td>",
"       <td rowspan=\"6\">",
"        13.6 g",
"       </td>",
"       <td class=\"subtitle2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"6\">",
"        Amount of alcohol per week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Definition",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Standard drinks per week",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        As g of pure alcohol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Low risk",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        1-14",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"4\">",
"        182",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Moderate risk",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        15-34",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"4\">",
"        195-442",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        High risk",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        35+",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"4\">",
"        455",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\" colspan=\"7\">",
"        \"As a general guideline, persons should not drink more than two standard drinks in any day\". A standard drink is defined as 12 ounces of beer; 5 ounces of wine; or 1.5 ounces of spirits.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"10\">",
"        Czech Republic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        <em>",
"         National Institute of Public Health",
"        </em>",
"       </td>",
"       <td rowspan=\"2\">",
"        None",
"       </td>",
"       <td>",
"        0-24 g of alcohol per day is \"comparatively safe\"",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        0-16 g of alcohol per day is \"comparatively safe\"",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td colspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        The recommendations are for adults over 18, without any disease which \"could deteriorate because of alcohol (eg, epilepsy),\" not engaged in risky behaviors and not taking medicines interacting with alcohol.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"10\">",
"        Denmark",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        <em>",
"         Sundhedsstyrelsen",
"        </em>",
"       </td>",
"       <td rowspan=\"2\">",
"        12 g",
"       </td>",
"       <td colspan=\"2\">",
"        No more than 21 drinks per week",
"       </td>",
"       <td>",
"        252",
"       </td>",
"       <td>",
"        No more than 14 drinks per week",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td colspan=\"2\">",
"        168",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        Advises: \"Skip the drinks on every day/Save them for weekends or special days!\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"10\">",
"        Finland",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <em>",
"         Oy Alko AB",
"        </em>",
"       </td>",
"       <td>",
"        11 g",
"       </td>",
"       <td colspan=\"2\">",
"        No more than 15 drinks per week",
"       </td>",
"       <td>",
"        161",
"       </td>",
"       <td>",
"        No more than 10 drinks per week",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td colspan=\"2\">",
"        110",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"10\">",
"        France",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <em>",
"         Academy of Medicine",
"        </em>",
"       </td>",
"       <td>",
"        <strong>",
"         12 g",
"        </strong>",
"       </td>",
"       <td>",
"        Maximum of 5 drinks per day",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Maximum of 3 drinks per day",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td colspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"10\">",
"        Germany",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <em>",
"         No official guidelines",
"        </em>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td colspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"10\">",
"        Hungary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        17 g",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td colspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"10\">",
"        Iceland",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        9.5 g",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td colspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"10\">",
"        Ireland",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        <em>",
"         An Roinn Slainte (Department of Health)",
"        </em>",
"       </td>",
"       <td rowspan=\"2\">",
"        8 g",
"       </td>",
"       <td>",
"        Three units per day",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Two units per day",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td colspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        Advises: \"Less Is Better\" (1996).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"10\">",
"        Israel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <em>",
"         Ministry of Health",
"        </em>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td colspan=\"7\">",
"        \"No advice in relation to sensible levels of drinking\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"10\">",
"        Italy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"3\">",
"        <em>",
"         Ministero della Sanit&agrave;/Societ&agrave; Italiana di Nutrizione Umana",
"        </em>",
"       </td>",
"       <td rowspan=\"3\">",
"        10 g",
"       </td>",
"       <td>",
"        40 g per day, but 30 g for elderly men, which must not exceed 10 percent of the caloric intake",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <strong>",
"         30 g per day, but 25 g for elderly women, which must not exceed 10 percent of the caloric intake",
"        </strong>",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td colspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        The Ministero della Sanit&agrave; publishes guidance tables as part of LARN (National Recommended Energy and Nutrient Intake Levels).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        The tables give alcohol consumption limits for a range of body weights in men and women and for wine at 10 percent, 11 percent and 12 percent abv, and for spirits (superalcoholico) plus 11 percent abv wine.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"10\">",
"        Japan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <em>",
"         Ministry of Health and Welfare",
"        </em>",
"       </td>",
"       <td>",
"        19.75 g",
"       </td>",
"       <td>",
"        Two drinks (go's) of sake per day at the most",
"       </td>",
"       <td>",
"        39.5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td colspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"10\">",
"        Netherlands",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <em>",
"         Ministrie van Welzijn, Volksgezondheid en Cultuur",
"        </em>",
"       </td>",
"       <td>",
"        9.9 g",
"       </td>",
"       <td colspan=\"7\">",
"        The Dutch government adheres to the advice of the World Health Organisation that 'less is better' and suggests [\"two or three units a few times a week\"].",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"10\">",
"        New Zealand",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <em>",
"         Alcohol Advisory Council of New Zealand (ALAC)",
"        </em>",
"       </td>",
"       <td>",
"        10 g",
"       </td>",
"       <td>",
"        No more than 21 standard drinks per week and no more than six on any one occasion",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        210",
"       </td>",
"       <td>",
"        No more than 14 standard drinks per week and no more than four on any one occasion",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td colspan=\"2\">",
"        140",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"10\">",
"        Portugal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <em>",
"         Conselho Nacional de Alimentacao e Nutricao (CNAN)",
"        </em>",
"       </td>",
"       <td>",
"        14 g*",
"       </td>",
"       <td>",
"        Wine only. Estimates based on 150 ml serving. (source: ARISE)",
"       </td>",
"       <td>",
"        37.3",
"       </td>",
"       <td>",
"        261.1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        18.6",
"       </td>",
"       <td colspan=\"2\">",
"        130.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"10\">",
"        Romania",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <em>",
"         Health Ministry",
"        </em>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Up to 32.5 g as beer or 20.7 g as wine per day",
"       </td>",
"       <td>",
"        20.7-32.5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Up to 17.3 g as beer or 10.8 g as wine per day",
"       </td>",
"       <td>",
"        10.8-17.3",
"       </td>",
"       <td colspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"10\">",
"        Spain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        <em>",
"         INESIBA",
"        </em>",
"       </td>",
"       <td>",
"        <strong>",
"         10 g*",
"        </strong>",
"       </td>",
"       <td>",
"        40-44 g per day",
"       </td>",
"       <td>",
"        40-44",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        40-44 g per day",
"       </td>",
"       <td>",
"        40-44",
"       </td>",
"       <td colspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        <em>",
"         Ministry of Health &amp; Consumption",
"        </em>",
"       </td>",
"       <td rowspan=\"2\">",
"        <strong>",
"         10 g*",
"        </strong>",
"       </td>",
"       <td>",
"        30 g per day",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        20 g per day",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td colspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        Moderate drinking is considered to be 100-420 g of alcohol per week.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"10\">",
"        Basque Country",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <em>",
"         Department of Health &amp; Social Security",
"        </em>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Maximum of 1 g per Kg of body weight per day",
"       </td>",
"       <td>",
"        70&bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Maximum of 0.5 g per Kg of body weight per day",
"       </td>",
"       <td>",
"        28&Delta;",
"       </td>",
"       <td colspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"10\">",
"        Catalonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <em>",
"         Central Authority",
"        </em>",
"       </td>",
"       <td>",
"        8-10 g",
"       </td>",
"       <td colspan=\"7\">",
"        Advises not exceeding 40-50 g per day.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"10\">",
"        Sweden",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"10\">",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"10\">",
"        <em>",
"         Systembolaget",
"        </em>",
"       </td>",
"       <td rowspan=\"10\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"6\">",
"        Amount of alcohol per week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Men",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        Definition",
"       </td>",
"       <td class=\"subtitle3_left\">",
"        As 40 percent spirits",
"       </td>",
"       <td class=\"subtitle3_left\">",
"        As ml pure alcohol",
"       </td>",
"       <td class=\"subtitle3_left\">",
"        As g of pure alcohol",
"       </td>",
"       <td class=\"subtitle3_left\">",
"        As 40 percent spirits",
"       </td>",
"       <td class=\"subtitle3_left\">",
"        As ml pure alcohol",
"       </td>",
"       <td class=\"subtitle3_left\">",
"        As g of pure alcohol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Not dangerous",
"       </td>",
"       <td class=\"sublist_other\">",
"        Up to 15 cl &loz;",
"       </td>",
"       <td class=\"sublist_other\">",
"        60",
"       </td>",
"       <td class=\"sublist_other\">",
"        47",
"       </td>",
"       <td class=\"sublist_other\">",
"        Up to 12 cl &sect;",
"       </td>",
"       <td class=\"sublist_other\">",
"        48",
"       </td>",
"       <td class=\"sublist_other\">",
"        38",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Low risk",
"       </td>",
"       <td class=\"sublist_other\">",
"        Up to 40 cl",
"       </td>",
"       <td class=\"sublist_other\">",
"        160",
"       </td>",
"       <td class=\"sublist_other\">",
"        126",
"       </td>",
"       <td class=\"sublist_other\">",
"        Up to 30 cl",
"       </td>",
"       <td class=\"sublist_other\">",
"        120",
"       </td>",
"       <td class=\"sublist_other\">",
"        95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Intermediate risk",
"       </td>",
"       <td class=\"sublist_other\">",
"        Up to 75 cl",
"       </td>",
"       <td class=\"sublist_other\">",
"        300",
"       </td>",
"       <td class=\"sublist_other\">",
"        237",
"       </td>",
"       <td class=\"sublist_other\">",
"        Up to 55 cl",
"       </td>",
"       <td class=\"sublist_other\">",
"        220",
"       </td>",
"       <td class=\"sublist_other\">",
"        174",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        High risk",
"       </td>",
"       <td class=\"sublist_other\">",
"        Up to 125 cl",
"       </td>",
"       <td class=\"sublist_other\">",
"        500",
"       </td>",
"       <td class=\"sublist_other\">",
"        395",
"       </td>",
"       <td class=\"sublist_other\">",
"        Up to 95 cl",
"       </td>",
"       <td class=\"sublist_other\">",
"        380",
"       </td>",
"       <td class=\"sublist_other\">",
"        300",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Very high risk",
"       </td>",
"       <td class=\"sublist_other\">",
"        Over 125 cl",
"       </td>",
"       <td class=\"sublist_other\">",
"        Over 500",
"       </td>",
"       <td class=\"sublist_other\">",
"        Over 395",
"       </td>",
"       <td class=\"sublist_other\">",
"        Over 95 cl",
"       </td>",
"       <td class=\"sublist_other\">",
"        Over 380",
"       </td>",
"       <td class=\"sublist_other\">",
"        Over 300",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\" colspan=\"7\">",
"        <p>",
"         Notes:",
"        </p>",
"        <p>",
"         &loz;: or 5 bottles of beer, or two thirds of a bottle of wine.",
"        </p>",
"        <p>",
"         &sect;: or 4 bottles of beer or half a bottle of wine.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"10\">",
"        United Kingdom",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"3\">",
"        <em>",
"         Department of Health",
"        </em>",
"       </td>",
"       <td rowspan=\"3\">",
"        8 g",
"       </td>",
"       <td>",
"        \"Maximum health advantage\" for men over 40 lies between one and two units a day",
"       </td>",
"       <td>",
"        8-16 g",
"       </td>",
"       <td rowspan=\"3\">",
"        Advice on weekly consumption is avoided",
"       </td>",
"       <td>",
"        \"Maximum health advantage\" for postmenopausal women lies between one and two units a day",
"       </td>",
"       <td>",
"        8-16 g",
"       </td>",
"       <td colspan=\"2\" rowspan=\"3\">",
"        Advice on weekly consumption is avoided",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Regular consumption of between three and four units a day for men of all ages \"will not accrue significant health risk\"",
"       </td>",
"       <td>",
"        24-32 g",
"       </td>",
"       <td>",
"        Regular consumption of between two and three units a day by women of all ages \"will not accrue any significant health risk\"",
"       </td>",
"       <td>",
"        16-24 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consistently drinking four or more units a day is \"not advised as a sensible drinking level\"",
"       </td>",
"       <td>",
"        32 g+",
"       </td>",
"       <td>",
"        Consistently drinking three or more units a day is \"not advised as a sensible drinking level\"",
"       </td>",
"       <td>",
"        24 g+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"10\">",
"        United States",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"3\">",
"        <em>",
"         Department of Agriculture/Department of Health and Human Services",
"        </em>",
"       </td>",
"       <td rowspan=\"3\">",
"        14 g&yen;",
"       </td>",
"       <td>",
"        No more than two drinks per day",
"       </td>",
"       <td>",
"        28 g",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        No more than one drink per day",
"       </td>",
"       <td>",
"        14 g",
"       </td>",
"       <td colspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        A standard drink is defined as 12 ounces of regular beer (one bottle); a 5 ounce glass of wine; or 1.5 ounces of 80-proof distilled spirits.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        Advises: \"If you drink alcoholic beverages, do so in moderation, with meals, and when consumption does not put you or others at risk\".",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Approximate/unofficial figure.",
"     <br>",
"      &bull; For a 70 Kg man.",
"      <br>",
"       &Delta; For a 56 Kg woman.",
"       <br>",
"        &yen; Wine Institute suggests 12 g for wine.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     file://www.drinkingandyou.com/site/uk/biggy.htm.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_3_1073=[""].join("\n");
var outline_f1_3_1073=null;
var title_f1_3_1074="Patient information: Hamstring injury (The Basics)";
var content_f1_3_1074=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/87351\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/49/10002\">",
"         Thigh sleeve",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?19/39/20083\">",
"         Patient information: Exercise (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/0/39938\">",
"         Patient information: Muscle strain (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/42/7844\">",
"         Patient information: Exercise (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hamstring injury (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H175777006\">",
"      <span class=\"h1\">",
"       What is a hamstring injury?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The hamstrings are the muscles in the back of the thigh. A hamstring injury happens when 1 of these muscles gets stretched too much or too quickly, or works too hard. This sometimes makes the muscle tear.",
"     </p>",
"     <p>",
"      A hamstring injury also happens when a tendon in the back of the thigh stretches too much or tears. Tendons are strong bands of tissue that connect muscles to bones.",
"     </p>",
"     <p>",
"      Hamstring injuries happen most often when people are running or exercising.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H175777021\">",
"      <span class=\"h1\">",
"       What are the symptoms of a hamstring injury?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A hamstring injury causes sudden pain in the back of the thigh. Sometimes people feel a &ldquo;pop&rdquo; when the injury happens. The injury can also cause warmth or bruising in the back of the thigh.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H175777036\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. Your doctor or nurse should be able to tell if you have a hamstring injury by learning about your symptoms and doing an exam.",
"     </p>",
"     <p>",
"      But some people need tests. Depending on your symptoms, your doctor or nurse might order an imaging test such as an ultrasound or MRI scan. Imaging tests create pictures of the inside of the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H175777051\">",
"      <span class=\"h1\">",
"       How is a hamstring injury treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A hamstring injury usually gets better by itself, but it can take weeks to months to heal completely. Healing time depends on a person&rsquo;s age, how healthy he or she is, and how serious the injury is.",
"     </p>",
"     <p>",
"      To help with your symptoms, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Avoid doing activities or exercises that cause pain (until your symptoms improve) &ndash; In the meantime, you can continue to do other exercises and activities, as long as they don&rsquo;t cause pain or make your injury worse.",
"       </li>",
"       <li>",
"        Prop the affected leg up on pillows or a chair when you rest &ndash; This is helpful only for the first few days after an injury.",
"       </li>",
"       <li>",
"        Ice the injury &ndash; Put a cold gel pack, bag of ice, or bag of frozen vegetables on the area every 1 to 2 hours, for 15 minutes each time. Put a thin towel between the ice (or other cold object) and your skin. Use the ice (or other cold object) for at least 6 hours after the injury. Some people find it helpful to ice up to 2 days after an injury.",
"       </li>",
"       <li>",
"        Wrap your thigh muscles with an elastic bandage, other type of wrap, or fabric &ldquo;sleeve&rdquo; (",
"        <a class=\"graphic graphic_picture graphicRef83481 \" href=\"UTD.htm?9/49/10002\">",
"         picture 1",
"        </a>",
"        ) &ndash; This helps support your muscle.",
"       </li>",
"       <li>",
"        Take a pain-relieving medicine &ndash; If you have a lot of pain or a severe hamstring injury, your doctor will prescribe a strong pain medicine. If your hamstring injury is not severe, you can take an over-the-counter medicine such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        (sample brand name: Tylenol) or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil, Motrin).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      After your pain gets better, you can gently stretch and exercise your hamstring muscles. Stretches and exercises can help strengthen your muscles and keep them from getting too stiff. Your doctor or nurse will show you which stretches and exercises to do. Or he or she will have you work with a physical therapist (exercise expert).",
"     </p>",
"     <p>",
"      It&rsquo;s important to let your hamstring injury heal before you play sports or do other activities that use the muscles again. If you don&rsquo;t let your muscles heal, you are likely to get another hamstring injury.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H175777089\">",
"      <span class=\"h1\">",
"       Can a hamstring injury be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help prevent a hamstring injury, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Take time to warm up your muscles before you exercise. You can do this by walking or doing another light activity.",
"       </li>",
"       <li>",
"        Do the exercises to strengthen your hamstrings that your doctor or physical therapist shows you. This can help lower the chance that you will get another hamstring injury.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H175777104\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/0/39938?source=see_link\">",
"       Patient information: Muscle strain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/39/20083?source=see_link\">",
"       Patient information: Exercise (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=see_link\">",
"       Patient information: Exercise (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?1/3/1074?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 87351 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-CCFD8525CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_3_1074=[""].join("\n");
var outline_f1_3_1074=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H175777006\">",
"      What is a hamstring injury?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H175777021\">",
"      What are the symptoms of a hamstring injury?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H175777036\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H175777051\">",
"      How is a hamstring injury treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H175777089\">",
"      Can a hamstring injury be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H175777104\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/87351\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/49/10002\">",
"      Thigh sleeve",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=related_link\">",
"      Patient information: Exercise (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/39/20083?source=related_link\">",
"      Patient information: Exercise (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/0/39938?source=related_link\">",
"      Patient information: Muscle strain (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_3_1075="Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)";
var content_f1_3_1075=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15362\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/47/25343\">",
"         Deep veins of the leg",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?29/34/30242\">",
"         Patient information: Doppler ultrasound (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/60/24514\">",
"         Patient information: Factor V Leiden (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/11/14515\">",
"         Patient information: Latest medicines to prevent blood clots (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/42/27298\">",
"         Patient information: Staying healthy when you travel (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/16/21762\">",
"         Patient information: Superficial phlebitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/44/2755\">",
"         Patient information: Warfarin (Coumadin) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/2/32803\">",
"         Patient information: What can go wrong after a heart attack? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/17/35091\">",
"         Patient information: Chronic venous disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/44/12998\">",
"         Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/29/2517\">",
"         Patient information: Pulmonary embolism (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/15/21747\">",
"         Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/deep-vein-thrombosis-blood-clots-in-the-legs-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H384238871\">",
"      <span class=\"h1\">",
"       What is deep vein thrombosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Deep vein thrombosis is the medical term for blood clots in the deep veins of the leg (",
"      <a class=\"graphic graphic_figure graphicRef70603 \" href=\"UTD.htm?24/47/25343\">",
"       figure 1",
"      </a>",
"      ). Deep vein thrombosis, or &ldquo;DVT&rdquo; for short, can be dangerous.",
"     </p>",
"     <p>",
"      If a blood clot forms inside a blood vessel, it can clog the vessel and keep blood from getting where it needs to go. When that happens to one of the veins deep within the leg, blood can back up and cause swelling and pain.",
"     </p>",
"     <p>",
"      Another problem with blood clots in veins is that they can travel to other parts of the body and clog blood vessels there. Blood clots that form in the legs, for example, can wind up clogging blood vessels in the lungs. This can make it hard to breathe or even lead to death. When blood clots travel to the lungs and clog a blood vessel, doctors call it &ldquo;pulmonary embolism&rdquo; or &ldquo;PE.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H384238878\">",
"      <span class=\"h1\">",
"       What are the symptoms of DVT?",
"      </span>",
"      &nbsp;&mdash;&nbsp;DVT can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Swelling",
"       </li>",
"       <li>",
"        Pain",
"       </li>",
"       <li>",
"        Warmth and redness in the involved leg",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Sometimes clots form in the veins that are closer to the surface of the skin (in other words, not the deep ones). Those blood clots cause a different set of symptoms. Blood clots in the veins near the surface of the skin can cause pain, redness, or infection. These clots sometimes also cause the veins to harden and bulge into ridges that look like cords (often called varicose veins). This is most common with the veins below the knee.",
"     </p>",
"     <p>",
"      If you think you have a blood clot in your leg, call your doctor or nurse right away. Blood clots in the veins near the surface of the skin are not usually dangerous. But blood clots in the deep veins of the leg can be serious. Your doctor or nurse can run tests to find out if you do have a clot.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H384238885\">",
"      <span class=\"h1\">",
"       What are the symptoms of blood clots in the lungs?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Blood clots in the lungs can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Panting or trouble breathing",
"       </li>",
"       <li>",
"        Sharp, knife-like chest pain when you breathe in",
"       </li>",
"       <li>",
"        Coughing or coughing up blood",
"       </li>",
"       <li>",
"        A rapid heartbeat",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you get any of these symptoms, call 9-1-1. At the hospital, doctors can run tests to find out if you do have a clot. Blood clots in the lungs can lead to death.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H384238892\">",
"      <span class=\"h1\">",
"       How is DVT treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;DVT is treated with medicines that dissolve clots or keep them from getting bigger. Some of these medicines come in shots and others come in pills.",
"     </p>",
"     <p>",
"      People who have had DVT must usually take a medicine called",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"       warfarin",
"      </a>",
"      (brand name: Coumadin&reg;) for at least 3 months after their clot is found. This medicine helps keep new blood clots from forming. It is important because people who have DVT can get it again. Warfarin comes in a pill.",
"     </p>",
"     <p>",
"      If your doctor puts you on",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"       warfarin",
"      </a>",
"      , take it exactly as directed. If you forget or miss a dose, call your doctor to find out what to do. When you start taking it, you will need to have your blood tested often. That&rsquo;s because the effects of warfarin can change over time. Your blood needs to be checked to see how the drug is working. If there are changes, your doctor may need to adjust your dose. At the wrong doses, the drug can either stop working or lead to serious bleeding.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H384238899\">",
"      <span class=\"h1\">",
"       Can I do anything on my own to prevent blood clots?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. People sometimes form clots because they have been sitting still for too long. People who travel on long airplane flights, for example, are at increased risk of blood clots. But you can prevent a clot during a long flight by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Standing up and walking around every hour or two",
"       </li>",
"       <li>",
"        Not smoking just before your trip",
"       </li>",
"       <li>",
"        Wearing loose, comfortable clothes",
"       </li>",
"       <li>",
"        Shifting your position while seated, and moving your legs and feet often",
"       </li>",
"       <li>",
"        Drinking plenty of fluids",
"       </li>",
"       <li>",
"        Wearing knee-high compression stockings",
"       </li>",
"       <li>",
"        Avoiding alcohol and medicines that make you sleepy, because they can impair your ability to move around",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H384238906\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/42/27298?source=see_link\">",
"       Patient information: Staying healthy when you travel (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/2/32803?source=see_link\">",
"       Patient information: What can go wrong after a heart attack? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/44/2755?source=see_link\">",
"       Patient information: Warfarin (Coumadin) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30242?source=see_link\">",
"       Patient information: Doppler ultrasound (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24514?source=see_link\">",
"       Patient information: Factor V Leiden (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/11/14515?source=see_link\">",
"       Patient information: Latest medicines to prevent blood clots (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/16/21762?source=see_link\">",
"       Patient information: Superficial phlebitis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/17/35091?source=see_link\">",
"       Patient information: Chronic venous disease (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"       Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2517?source=see_link\">",
"       Patient information: Pulmonary embolism (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=see_link\">",
"       Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?1/3/1075?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15362 Version 7.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-AB4CE9AEE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_3_1075=[""].join("\n");
var outline_f1_3_1075=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H384238871\">",
"      What is deep vein thrombosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H384238878\">",
"      What are the symptoms of DVT?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H384238885\">",
"      What are the symptoms of blood clots in the lungs?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H384238892\">",
"      How is DVT treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H384238899\">",
"      Can I do anything on my own to prevent blood clots?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H384238906\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15362\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/47/25343\">",
"      Deep veins of the leg",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/17/35091?source=related_link\">",
"      Patient information: Chronic venous disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=related_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30242?source=related_link\">",
"      Patient information: Doppler ultrasound (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24514?source=related_link\">",
"      Patient information: Factor V Leiden (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/11/14515?source=related_link\">",
"      Patient information: Latest medicines to prevent blood clots (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2517?source=related_link\">",
"      Patient information: Pulmonary embolism (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/42/27298?source=related_link\">",
"      Patient information: Staying healthy when you travel (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/16/21762?source=related_link\">",
"      Patient information: Superficial phlebitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/44/2755?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/2/32803?source=related_link\">",
"      Patient information: What can go wrong after a heart attack? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_3_1076="Lung cancer risks, symptoms, and diagnosis";
var content_f1_3_1076=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?1/3/1076/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/3/1076/contributors\" id=\"au823\">",
"       Karl W Thomas, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?1/3/1076/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/3/1076/contributors\" id=\"se4114\">",
"       James R Jett, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?1/3/1076/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/3/1076/contributors\" id=\"de7369\">",
"       Michael E Ross, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?1/3/1076?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Lung cancer is a serious health problem that affects many people and their families. Lung cancer is the leading cause of cancer death in the United States. It is usually caused by cigarette smoke, but there are other factors in the family and in the home or workplace that can increase the risk of lung cancer.",
"    </p>",
"    <p>",
"     When a person develops lung cancer, tests are done to determine the type of lung cancer and if it has spread. When a cancer spreads, this is called metastasis. The size and spread of cancer are combined into a scale that is called the cancer stage. The stage is an important feature used to help decide what treatments can be used. &nbsp;",
"    </p>",
"    <p>",
"     This article will review the risks for developing lung cancer and the different types of lung cancer. Next, this article will discuss the signs and symptoms of lung cancer and the medical testing required to confirm the diagnosis. Finally, this article will review the process of determining the cancer&rsquo;s size and location for staging.",
"    </p>",
"    <p>",
"     The treatment of lung cancer is discussed separately.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?40/22/41314?source=see_link\">",
"        \"Patient information: Non-small cell lung cancer treatment; stage I to III cancer (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?16/63/17396?source=see_link\">",
"        \"Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?22/8/22659?source=see_link\">",
"        \"Patient information: Small cell lung cancer treatment (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     More detailed information about lung cancer is available by subscription. (See",
"     <a class=\"local\" href=\"#H13\">",
"      'Professional level information'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      RISKS FOR LUNG CANCER",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Smoking",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cigarette smoking is the biggest risk factor for lung cancer. As an example, smoking is estimated to cause 85 percent of all lung cancers in the United States. A smoker's risk of developing lung cancer is 10 to 30 times greater than that of a nonsmoker. All forms of tobacco and smoking, including pipes, cigars, and chewing tobacco, are major risk factors for cancers of the mouth, throat, and lungs. The risk of lung cancer increases with the number of cigarettes smoked and the number of years of smoking.",
"    </p>",
"    <p>",
"     The risk of cancer remains high for several years after quitting smoking but the risk does go down within 5 to 10 years after quitting. A former smoker's risk of lung cancer is never as low as a nonsmoker's risk.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Environmental factors",
"     </span>",
"     &nbsp;&mdash;&nbsp;Substances at work or in the environment can increase a person's risk of developing lung cancer. In parts of the world where fuel such as wood or coal are widely used for cooking and heating, these may be important contributors to the risk of lung cancer. Other important factors include secondhand tobacco smoke, asbestos, arsenic, radiation, and some chemicals. Dust and fumes from nickel, chromium, and other metals may also increase the risk of lung cancer.",
"    </p>",
"    <p>",
"     Another important risk factor for lung cancer is radon in the home. Radon is a radioactive gas that occurs naturally in the ground. Radon can leak out of the ground and then become trapped in houses or buildings mainly in the basement, where it is then inhaled. You cannot see or smell radon, which is why testing for radon is often recommended (see",
"     <a class=\"external\" href=\"file://www.epa.gov/radon/pubs/citguide.html\">",
"      www.epa.gov/radon/pubs/citguide.html",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Age and genetic risk factors",
"     </span>",
"     &nbsp;&mdash;&nbsp;The risk of developing lung cancer increases with age. Lung cancer can occur in young people, although it is unusual in people younger than 40 years old. After age 40, the risk for developing lung cancer slowly increases every year.",
"    </p>",
"    <p>",
"     Some people have a genetic risk or predisposition for lung cancer. Anyone with a first-degree relative (parent, brother, sister) with lung cancer has a higher risk of developing lung cancer themselves.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H761926217\">",
"     <span class=\"h1\">",
"      SCREENING FOR LUNG CANCER",
"     </span>",
"    </p>",
"    <p>",
"     The most important factor in reducing the risks from lung cancer is to avoid smoking. For those individuals who are at increased risk of lung cancer because of smoking, screening with low dose computed tomography may be recommended. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/28/5570?source=see_link\">",
"      \"Patient information: Lung cancer prevention and screening (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      LUNG CANCER SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Most people with lung cancer have one or more symptoms. However, the symptoms of lung cancer are similar to the symptoms of other more common problems. If you are concerned about your symptoms, talk to your doctor or nurse.",
"    </p>",
"    <p>",
"     The most common symptoms of lung cancer include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Cough &mdash; Lung cancer can cause a new cough or a change in a chronic cough. The cough can be a dry or may produce sputum (phlegm), which can contain blood. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?27/34/28195?source=see_link\">",
"        \"Patient information: Chronic cough in adults (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Shortness of breath",
"      </li>",
"      <li>",
"       Wheezing, a whistling sound when you breathe",
"      </li>",
"      <li>",
"       Chest pain can develop and may be dull, sharp, or stabbing",
"      </li>",
"      <li>",
"       Voice hoarseness",
"      </li>",
"      <li>",
"       Headache and swelling of the face, arms, or neck",
"      </li>",
"      <li>",
"       Arm, shoulder, and neck pain can be caused by a tumor in the top of the lungs (called a Pancoast tumor). Other symptoms can include weakening of the hand muscles (due to pressure on the nerve that stimulates the arm), a droopy eyelid, and blurred vision.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      INITIAL TESTING AND DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     If you have symptoms that suggest lung cancer, your doctor or nurse will perform an examination. If your findings are still concerning, more tests including blood work and x-rays or scans will then be ordered. &nbsp;",
"    </p>",
"    <p>",
"     If the chest X-ray or scans show an abnormal growth that could be a tumor, additional testing is performed to make a diagnosis. Usually, a piece of the growth will need to be removed and examined under a microscope. This procedure is called a biopsy. &nbsp;",
"    </p>",
"    <p>",
"     A biopsy can be done in one of several ways:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Bronchoscopy is a procedure where a flexible tube with a camera is inserted under sedation through your mouth or nose and then into the windpipe (called the trachea). This procedure is described in detail separately. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?32/14/32993?source=see_link\">",
"        \"Patient information: Flexible bronchoscopy (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       CT-guided fine needle biopsy is performed by locating the tumor with a CT scan and inserting a thin needle through the skin, into the lung, to remove a tiny sample of tissue.",
"      </li>",
"      <li>",
"       Needle aspiration is performed by inserting a needle into lumps or lymph nodes that can be felt under the skin or into fluid collections in the chest.",
"      </li>",
"      <li>",
"       Surgery may be needed to remove the tumor if the tumor is small and it is not possible to get a sample of tissue any other way.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      TYPES OF LUNG CANCER",
"     </span>",
"    </p>",
"    <p>",
"     There are many different kinds of lung cancer. However, there are two main categories:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Small cell lung cancer is found in about 10 to 15 percent of patients.",
"      </li>",
"      <li>",
"       Non-small cell lung cancer (often abbreviated NSCLC) includes other types of lung cancer and is found in the remaining 85 to 90 percent of patients. There are subcategories of NSCLC, the most common of which are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The reason that small cell cancer is separated from non-small cell cancers is that small cell cancers behave differently and are treated differently than non-small cell cancers. Small cell cancer tends to be more aggressive and can spread quickly.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      STAGING NON-SMALL CELL LUNG CANCER",
"     </span>",
"    </p>",
"    <p>",
"     Once lung cancer is diagnosed, the next step is to review its size, to determine its exact location and to find out if it has spread. This process is called staging. Determining the stage of a lung cancer can be complicated because many features of the tumor are used at the same time. The stage of non-small cell cancer is based on:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       The size and location of the tumor",
"      </li>",
"      <li>",
"       Whether the tumor has invaded lymph nodes and tissues inside the chest",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Whether the tumor has spread to places outside the chest (for example lung cancer can spread (metastasize) to places like the lymph nodes or adrenal glands or elsewhere)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Non-small cell lung cancer stages range from I to IV. In general, the lower number (stages I and II) suggest that the tumor is smaller and has not spread far. In comparison, the higher numbers (stage III and IV) suggest that the tumor is larger or has metastasized. &nbsp;",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Stage I &mdash; The tumor is smaller than or equal to 5 cm in maximum diameter and has not spread to any other tissues or lymph nodes (",
"       <a class=\"graphic graphic_figure graphicRef53379 \" href=\"UTD.htm?26/31/27120\">",
"        figure 1",
"       </a>",
"       ). (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?40/22/41314?source=see_link\">",
"        \"Patient information: Non-small cell lung cancer treatment; stage I to III cancer (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Stage II &mdash;Stage II means that the tumor is either between 3 and 7 cm in size, or it has spread to the lymph nodes, or it has invaded the tissues surrounding the lung, or it has started to invade the large bronchial tubes (",
"       <a class=\"graphic graphic_figure graphicRef60551 \" href=\"UTD.htm?22/59/23473\">",
"        figure 2",
"       </a>",
"       ). (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?40/22/41314?source=see_link\">",
"        \"Patient information: Non-small cell lung cancer treatment; stage I to III cancer (Beyond the Basics)\"",
"       </a>",
"       .) &nbsp;",
"      </li>",
"      <li>",
"       Stage IIIA &mdash; Stage IIIA disease means that the tumor can be bigger than 7 cm, or has spread to the lymph nodes in the center of the chest (called the mediastinum) or has spread to the rib cage, heart, swallowing tube (called the esophagus) or to the trachea (",
"       <a class=\"graphic graphic_figure graphicRef86985 \" href=\"UTD.htm?7/16/7426\">",
"        figure 3",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Stage IIIB &ndash; Stage IIIB disease means that the tumor has spread to lymph nodes on the other side of the mediastinum or to the lymph nodes above or behind the clavicle (collar bone). Stage IIIB also includes large tumors that have spread to the rib cage, heart, swallowing tube (called the esophagus) or to the trachea when there is involvement of the mediastinal lymph nodes (",
"       <a class=\"graphic graphic_figure graphicRef86986 \" href=\"UTD.htm?10/24/10627\">",
"        figure 4",
"       </a>",
"       ). &nbsp;",
"      </li>",
"      <li>",
"       Stage IV &mdash; Stage IV means that the cancer has spread outside of the chest or has spread to a critical location or has caused some complication. Possible complications are that the cancer has caused fluid to collect around the lung or heart (called a malignant effusion), or it has spread to the opposite side of the chest, has spread to outside the chest (",
"       <a class=\"graphic graphic_figure graphicRef74377 \" href=\"UTD.htm?6/8/6278\">",
"        figure 5",
"       </a>",
"       ). (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?16/63/17396?source=see_link\">",
"        \"Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In general, lower-stage cancers require different kinds of treatment than do higher-stage cancers. Treatment options for early stages may include surgery to remove the cancer entirely while later stage cancers may also be treated with medications (chemotherapy) or radiation. Some higher stage tumors have spread beyond the point where cure is possible and treatment for these may include medications to treat pain and discomfort.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      STAGING SMALL CELL LUNG CANCER",
"     </span>",
"    </p>",
"    <p>",
"     Technical staging for small cell cancer is exactly the same as for non-small cell cancer. However, treatment options are usually determined by a much more simple system. This is because SCLC has different growth patterns and a different prognosis. SCLC is categorized more commonly as either \"limited\" or \"extensive\" disease. This system helps to determine which treatment will be most effective.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Limited disease &mdash; This refers to small cell lung cancers that are confined to one side of the chest and lymph nodes.",
"      </li>",
"      <li>",
"       Extensive disease &mdash; This refers to small cell lung cancer that has spread to the opposite side of the chest or has metastasized (spread) to distant locations outside the chest.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The treatment and prognosis of SCLC depends upon whether disease is limited or extensive. This is discussed in detail in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/8/22659?source=see_link\">",
"      \"Patient information: Small cell lung cancer treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     Progress in treating lung cancer requires better treatments. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies. Clinical trials are conducted around the world. Ask for more information about clinical trials, or read about clinical trials at:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"        file://clinicaltrials.gov/",
"       </a>",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784981589\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3704199\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/34/35363?source=see_link\">",
"      Patient information: Lung cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/44/3779?source=see_link\">",
"      Patient information: Non-small cell lung cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/38/24162?source=see_link\">",
"      Patient information: Small cell lung cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/13/11475?source=see_link\">",
"      Patient information: Lung cancer screening (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/17/3347?source=see_link\">",
"      Patient information: Asbestos exposure (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/23/24946?source=see_link\">",
"      Patient information: Multiple pulmonary nodules (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/1/23570?source=see_link\">",
"      Patient information: Single pulmonary nodule (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3704249\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/22/41314?source=see_link\">",
"      Patient information: Non-small cell lung cancer treatment; stage I to III cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/63/17396?source=see_link\">",
"      Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/8/22659?source=see_link\">",
"      Patient information: Small cell lung cancer treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/34/28195?source=see_link\">",
"      Patient information: Chronic cough in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/14/32993?source=see_link\">",
"      Patient information: Flexible bronchoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16282?source=see_link\">",
"      Overview of the risk factors, pathology, and clinical manifestations of lung cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link\">",
"      Cigarette smoking and other risk factors for lung cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28586?source=see_link\">",
"      Screening for lung cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=see_link\">",
"      Overview of the initial evaluation, treatment and prognosis of lung cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=see_link\">",
"      Pathology of lung malignancies",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=see_link\">",
"      Pathobiology and staging of small cell carcinoma of the lung",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/10/19625?source=see_link\">",
"      Role of imaging in the staging of non-small cell lung cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15400?source=see_link\">",
"      Preoperative evaluation for lung resection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/5/1114?source=see_link\">",
"      Management of stage I and stage II non-small cell lung cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39498?source=see_link\">",
"      Management of stage III non-small cell lung cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/57/21401?source=see_link\">",
"      Overview of the treatment of advanced non-small cell lung cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14809?source=see_link\">",
"      Personalized, genotype-directed therapy for advanced non-small cell lung cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link\">",
"      First-line chemotherapy for patients with extensive stage small cell lung cancer",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.gov/cancertopics/types/lung\">",
"      www.cancer.gov/cancertopics/types/lung",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/patient/Cancer+Types/Lung+Cancer\">",
"      www.cancer.net/patient/Cancer+Types/Lung+Cancer",
"     </a>",
"     ) [",
"     <a class=\"abstract\" href=\"UTD.htm?1/3/1076/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 15, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?1/3/1076?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1076/abstract/1\">",
"      Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 2009; 136:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1076/abstract/2\">",
"      Pretreatment evaluation of non-small-cell lung cancer. The American Thoracic Society and The European Respiratory Society. Am J Respir Crit Care Med 1997; 156:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1076/abstract/3\">",
"      Bach PB, Silvestri GA, Hanger M, et al. Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:69S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1076/abstract/4\">",
"      Spiro SG, Gould MK, Colice GL, American College of Chest Physicians. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007; 132:149S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1076/abstract/5\">",
"      Silvestri GA, Gould MK, Margolis ML, et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007; 132:178S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1076/abstract/6\">",
"      Simon GR, Turrisi A, American College of Chest Physicians. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:324S.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f1_3_1076=[""].join("\n");
var outline_f1_3_1076=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           RISKS FOR LUNG CANCER",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H761926217\">",
"           SCREENING FOR LUNG CANCER",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           LUNG CANCER SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           INITIAL TESTING AND DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           TYPES OF LUNG CANCER",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           STAGING NON-SMALL CELL LUNG CANCER",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           STAGING SMALL CELL LUNG CANCER",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/31/27120\" title=\"figure 1\">",
"           Lung ca I PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/59/23473\" title=\"figure 2\">",
"           Lung ca II PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/16/7426\" title=\"figure 3\">",
"           Stage IIIA NSCLC",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/24/10627\" title=\"figure 4\">",
"           Stage IIIB NSCLC",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/8/6278\" title=\"figure 5\">",
"           Lung ca IV PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f1_3_1077="Rosuvastatin: Patient drug information";
var content_f1_3_1077=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Rosuvastatin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"     see \"Rosuvastatin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/54/42854?source=see_link\">",
"     see \"Rosuvastatin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F219522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Crestor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F219523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Rosuvastatin;",
"     </li>",
"     <li>",
"      CO Rosuvastatin;",
"     </li>",
"     <li>",
"      Crestor&reg;;",
"     </li>",
"     <li>",
"      Jamp-Rosuvastatin;",
"     </li>",
"     <li>",
"      Mylan-Rosuvastatin;",
"     </li>",
"     <li>",
"      PMS-Rosuvastatin;",
"     </li>",
"     <li>",
"      RAN&trade;-Rosuvastatin;",
"     </li>",
"     <li>",
"      Sandoz-Rosuvastatin;",
"     </li>",
"     <li>",
"      Teva-Rosuvastatin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13927492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower cholesterol and other harmful types of cholesterol in the body. Good cholesterol (HDL) levels rise.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691358",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower triglycerides.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691638",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to slow the progress of heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691456",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop heart attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop strokes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702893",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to rosuvastatin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703199",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Active liver disease or a rise in liver enzymes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696863",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take colestipol or cholestyramine within 4 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid or limit drinking wine, beer, or mixed drinks to less than 3 drinks a day. Drinking too much alcohol may raise your chance of liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698255",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698663",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11229 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-81EFD22CC2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_3_1077=[""].join("\n");
var outline_f1_3_1077=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219522\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219523\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13927492\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026249\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026248\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026253\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026254\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026256\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026251\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026252\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026257\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026258\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=related_link\">",
"      Rosuvastatin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/54/42854?source=related_link\">",
"      Rosuvastatin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_3_1078="Gemtuzumab ozogamicin: Drug information";
var content_f1_3_1078=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gemtuzumab ozogamicin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F175896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Monoclonal Antibody",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F175882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients should receive diphenhydramine 50 mg orally and acetaminophen 650-1000 mg orally 1 hour prior to administration of each dose. Acetaminophen dosage should be repeated as needed every 4 hours for 2 additional doses. Pretreatment with methylprednisolone may ameliorate infusion-related symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute myeloid leukemia (unlabeled/investigational use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &lt;60 years: 9 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     infused over 2 hours. A full treatment course is a total of 2 doses administered with 14-28 days between doses (Larson, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &ge;60 years: 9 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     infused over 2 hours. A full treatment course is a total of 2 doses administered with 14-28 days between doses (Larson, 2002; Larson, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute promyelocytic leukemia (unlabeled/investigational use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Single-agent therapy: 6 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     infused over 2 hours on days 1 and 15; for patients testing PCR negative after 2 doses, a third dose was administered (LoCoco, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Combination therapy (high-risk patients; Ravandi, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Induction: 9 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     as a single dose on day 1 (in combination with arsenic trioxide and tretinoin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Post remission therapy (if arsenic trioxide or tretinoin discontinued due to toxicity): 9 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once every 4-5 weeks until 28 weeks after complete remission.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F175883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15897363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15897364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F6786283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dyspnea or significant hypotension: Interrupt infusion; monitor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Anaphylaxis, pulmonary edema, acute respiratory distress syndrome: Strongly consider discontinuing treatment",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F175845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F10335467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No longer commercially available in the U.S. market for new patients. Available in Canada through a special access program.",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11238299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As of June 2010, gemtuzumab has been withdrawn from the U.S. market and is no longer commercially available to new patients; gemtuzumab is only  available in the U.S. under an Investigational New Drug (IND) protocol.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In Canada, gemtuzumab is available through a special access program (access information is available from Health Canada).",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F175863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not administer as I.V. push or bolus. Administer via I.V. infusion, over at least 2 hours through a low protein-binding (0.2-1.2 micron) in-line filter. Protect from light during infusion. Premedicate with acetaminophen and diphenhydramine prior to each infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F175862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to safety concerns, as well as lack of clinical benefit demonstrated in a post-approval clinical trial, gemtuzumab was withdrawn from the U.S. commercial market in 2010.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F2317121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of relapsed or refractory CD33-positive acute myeloid leukemia (AML); salvage therapy for acute promyelocytic leukemia (APL)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3401641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Gemtuzumab may be confused with gemcitabine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F175894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Cerebral hemorrhage, hyper-/hypotension, peripheral edema, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Anxiety, chills, depression, dizziness, fever, headache, insomnia, intracranial hemorrhage, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Bruising, petechiae, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia, hypocalcemia, hypokalemia, hypomagnesemia, hypophosphatemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, dyspepsia, gingival hemorrhage, melena, mucositis, nausea, stomatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Genitourinary: Vaginal bleeding, vaginal hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hematologic:  Anemia, disseminated intravascular coagulation (DIC), hemorrhage, leukopenia, lymphopenia, neutropenia (median recovery 40-51 days), neutropenic fever, thrombocytopenia (median recovery 36-51 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased, ascites, AST increased, hyperbilirubinemia, LDH increased, prothrombin time increased, PTT increased, sinusoidal obstruction syndrome (SOS; veno-occlusive disease; higher frequency in patients with prior history of or subsequent hematopoietic stem cell transplant)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Local: Local reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, myalgia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Renal: Creatinine increased, hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, epistaxis, hypoxia, pharyngitis, pneumonia, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Cutaneous herpes simplex, infection, infusion reaction, sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infrequent and/or case reports (limited to important or life-threatening): Acute respiratory distress syndrome, anaphylaxis, bradycardia, Budd-Chiari syndrome, gastrointestinal hemorrhage, hepatic failure, hepatosplenomegaly, hypersensitivity reactions, jaundice, neutropenic sepsis, noncardiogenic pulmonary edema, portal vain thrombosis, pulmonary hemorrhage, renal impairment, renal failure (including renal failure secondary to tumor lysis syndrome)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F175866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to gemtuzumab ozogamicin, calicheamicin derivatives, or any component of the formulation; patients with anti-CD33 antibody",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F175849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      Severe myelosuppression occurs in all patients at recommended dosages.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      Has been associated with hepatotoxicity, including severe hepatic sinusoidal obstruction syndrome (SOS; formerly called veno-occlusive disease [VOD]).",
"     </b>",
"     Symptoms of SOS include right upper quadrant pain, rapid weight gain, ascites, hepatomegaly, and bilirubin/transaminase elevations. Risk may be increased by combination chemotherapy, underlying hepatic disease, or hematopoietic stem cell transplant.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity/infusion reaction:",
"     <b>",
"      Severe hypersensitivity reactions (including anaphylaxis) and other infusion-related reactions may occur.",
"     </b>",
"     Infusion-related events are common, generally reported to occur with the first dose after the end of the 2-hour intravenous infusion. These symptoms usually resolved after 2-4 hours with a supportive therapy of acetaminophen, diphenhydramine, and intravenous fluids. Other severe and potentially fatal infusion related pulmonary events (including dyspnea and hypoxia) have been reported infrequently. High peripheral blast counts may increase the risk of severe reactions (consider leukoreduction with hydroxyurea or leukapheresis to lower WBC to &lt;30,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     prior to therapy initiation). Fewer infusion-related events were observed after the second dose. Postinfusion reactions (may include fever, chills, hypotension, or dyspnea) may occur during the first 24 hours after administration. Consider discontinuation in patients who develop severe infusion-related reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary events: In addition to infusion-related pulmonary events, gemtuzumab therapy is also associated with acute respiratory distress syndrome, pulmonary infiltrates, pleural effusion, noncardiogenic pulmonary edema, and pulmonary insufficiency. Risk for pulmonary events may be increased with WBC &ge;30,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     . Symptomatic intrinsic lung disease may increase the risk for severe pulmonary reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor lysis syndrome: May occur as a consequence of leukemia treatment, adequate hydration and prophylactic allopurinol must be instituted prior to use. Other methods to lower WBC &lt;30,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     may be considered (hydroxyurea or leukapheresis) to minimize the risk of tumor lysis syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Combination chemotherapy: An increased number of deaths have been reported in patients receiving gemtuzumab in combination with chemotherapy, compared to those receiving chemotherapy alone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F175854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abciximab: May enhance the potential for allergic or hypersensitivity reactions to Monoclonal Antibodies. Also may cause thrombocytopenia or diminished therapeutic effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F175867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated teratogenic effects, fetal loss, and maternal toxicity. There are no adequate and well-controlled studies in pregnant women. May cause fetal harm when administered to a pregnant woman. Women of childbearing potential should avoid becoming pregnant while receiving treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F175887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16265827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if gemtuzumab ozogamicin is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F175859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor vital signs during the infusion and for 4 hours following the infusion. Monitor for signs/symptoms of postinfusion reaction. Monitor electrolytes, liver function, CBC with differential and platelets frequently. Monitor for signs and symptoms of hepatic sinusoidal obstruction syndrome (SOS; veno-occlusive disease; weight gain, right upper quadrant abdominal pain, hepatomegaly, ascites).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F175868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Mylotarg (AR, BR, CO, GR, IL, KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F175848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antibody to CD33 antigen, which is expressed on leukemic blasts in 80% of AML patients. Binds to the CD33 antigen, resulting in internalization of the antibody-antigen complex. Following internalization, the calicheamicin derivative is released inside the myeloid cell. The calicheamicin derivative binds to DNA resulting in double strand breaks and cell death. Pluripotent stem cells and nonhematopoietic cells are not affected.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F175865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      ss",
"     </sub>",
"     : Adults: Initial dose: 21 L; Repeat dose: 10 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Total calicheamicin: Initial: 41-45 hours, Repeat dose: 60-64 hours; Unconjugated: 100-143 hours (no change noted in repeat dosing)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Burnett AK, Hills RK, Milligan D, et al, &ldquo;Identification of Patients With Acute Myeloblastic Leukemia who Benefit from the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(4):369-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/3/1078/abstract-text/21172891/pubmed\" id=\"21172891\" target=\"_blank\">",
"        21172891",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larson RA, Boogaerts M, Estey E, et al, &ldquo;Antibody-Targeted Chemotherapy of Older Patients With Acute Myeloid Leukemia in First Relapse Using Mylotarg (Gemtuzumab Ozogamicin),&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 2002, 16(9):1627-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/3/1078/abstract-text/12200674/pubmed\" id=\"12200674\" target=\"_blank\">",
"        12200674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larson RA, Sievers EL, Stadtmauer EA, et al, \"Final Report of the Efficacy and Safety of Gemtuzumab Ozogamicin (Mylotarg) in Patients With CD33-Positive Acute Myeloid Leukemia in First Recurrence,\"",
"      <i>",
"       Cancer",
"      </i>",
"      , 2005, 104(7):1442-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/3/1078/abstract-text/16116598/pubmed\" id=\"16116598\" target=\"_blank\">",
"        16116598",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lo-Coco F, Cimino G, Breccia M, et al, \"Gemtuzumab Ozogamicin (Mylotarg) as a Single Agent for Molecularly Relapsed Acute Promyelocytic Leukemia,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2004, 104(7):1995-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/3/1078/abstract-text/15187030/pubmed\" id=\"15187030\" target=\"_blank\">",
"        15187030",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ravandi F, Estey E, Jones D, et al, &ldquo;Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(4):504-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/3/1078/abstract-text/19075265/pubmed\" id=\"19075265\" target=\"_blank\">",
"        19075265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanz MA, Grimwade D, Tallman MS, et al, &ldquo;Management of Acute Promyelocytic Leukemia: Recommendations From an Expert Panel on Behalf of the European LeukemiaNet,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2009, 113(9):1875-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/3/1078/abstract-text/18812465/pubmed\" id=\"18812465\" target=\"_blank\">",
"        18812465",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sievers EL, Larson RA, Stadtmauer EA, et al, &ldquo;Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(13):3244-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/3/1078/abstract-text/11432892/pubmed\" id=\"11432892\" target=\"_blank\">",
"        11432892",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8968 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-C38B34FA94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_3_1078=[""].join("\n");
var outline_f1_3_1078=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175896\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175882\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175883\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897363\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897364\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6786283\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175845\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10335467\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11238299\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175863\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175862\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2317121\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3401641\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175894\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175866\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175849\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299395\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175854\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175867\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175887\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265827\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175859\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175868\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175848\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175865\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8968\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8968|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_3_1079="Cannabis use disorders: Epidemiology, comorbidity, and pathogenesis";
var content_f1_3_1079=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cannabis use disorders: Epidemiology, comorbidity, and pathogenesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/3/1079/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/3/1079/contributors\">",
"     John A Bailey, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/3/1079/contributors\">",
"     Robert L DuPont, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/3/1079/contributors\">",
"     Scott A Teitelbaum, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/3/1079/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/3/1079/contributors\">",
"     Andrew J Saxon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/3/1079/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/3/1079/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/3/1079/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 11, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical syndromes resulting from cannabis use include intoxication, abuse, and dependence. These terms are defined in the DSM-IV-TR (Diagnostic and Statistical Manual, Fourth Edition, Text Revision) as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intoxication develops after ingestion of a substance and is characterized by a reversible syndrome of maladaptive behavioral or psychological changes, such as mood lability, cognitive impairment, or poor judgment.",
"     </li>",
"     <li>",
"      Abuse is a problematic pattern of substance use that results in poor role functioning, interpersonal difficulties, recurrent substance use in physically hazardous situations, or repeated legal difficulties.",
"     </li>",
"     <li>",
"      Dependence is a maladaptive pattern of substance use manifested by such symptoms as repeated substance ingestion despite physical or psychological problems caused by the substance, ingesting larger amounts of the substance over longer periods of time, unsuccessful efforts to limit substance use, tolerance to the substance's effects, and physiologic withdrawal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The psychoactive properties of cannabis are primarily due to delta-9-tetrahydrocannabinol (THC) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/2\">",
"     2",
"    </a>",
"    ]. The THC content of marijuana has increased significantly since the late 1960s from approximately 1 to 5 percent to as much as 10 to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/1\">",
"     1",
"    </a>",
"    ]. This increased potency may contribute to increased rates of dependence.",
"   </p>",
"   <p>",
"    The epidemiology, comorbidity, and pathogenesis of cannabis use, cannabis abuse, and cannabis dependence in adults will be reviewed here. Other issues related to cannabis abuse and dependence are discussed separately. Treatment of medical conditions such as chemotherapy-induced emesis and cancer pain with cannabinoids are discussed separately. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21783?source=see_link\">",
"     \"Cannabis use disorders: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19208?source=see_link\">",
"     \"Characteristics of antiemetic drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19208?source=see_link&amp;anchor=H11#H11\">",
"     \"Characteristics of antiemetic drugs\", section on 'Cannabinoids'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=see_link&amp;anchor=H13#H13\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\", section on 'Cannabinoids'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4554?source=see_link\">",
"     \"Cannabis use disorders: Treatment, prognosis, and long-term medical effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262913216\">",
"    <span class=\"h1\">",
"     STREET TERMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slang terms used for marijuana or cannabis include &ldquo;pot,&rdquo; &ldquo;reefer,&rdquo; &ldquo;Mary Jane,&rdquo; &ldquo;hash,&rdquo; &ldquo;weed,&rdquo; &ldquo;hemp,&rdquo; &ldquo;blunt,&rdquo; &ldquo;ganja,&rdquo; &ldquo;roach,&rdquo; &ldquo;nail,&rdquo; and &ldquo;dube&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/3\">",
"     3",
"    </a>",
"    ]. Synthetic cannabinoids such as CP-47, 497, JWH-073, and JWH-175 have street names that include &ldquo;K2,&rdquo; &ldquo;spice,&rdquo; &ldquo;Zohai,&rdquo; and &ldquo;eclipse&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cannabis is cultivated in nearly every country in the world [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/5\">",
"     5",
"    </a>",
"    ]. The plant is processed to produce three drug products, each of which may be ingested by smoking or eating:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dry leaves and flowers (herbal cannabis)",
"     </li>",
"     <li>",
"      Pressed, dry resin or secretion (hashish)",
"     </li>",
"     <li>",
"      Oil (hash oil)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common product used in North America is herbal cannabis, and in Europe it is hashish [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cannabis use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cannabis is the most commonly used illegal substance worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/5\">",
"     5",
"    </a>",
"    ]. Approximately 160 million people between the ages of 15 and 64 years used cannabis at least once in 2004, representing 4 percent of the world's population. In addition, cannabis use appears to be increasing.",
"   </p>",
"   <p>",
"    The World Health Organization World Mental Health Surveys show that the estimated cumulative (lifetime) incidence of cannabis use varies widely between different countries, and is lowest in the People's Republic of China and highest in the US (0.3 versus 42.4 percent of the population) (",
"    <a class=\"graphic graphic_table graphicRef78031 \" href=\"UTD.htm?23/51/24380\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/6\">",
"     6",
"    </a>",
"    ]. These surveys were conducted in 17 countries between 2001 and 2005, and sampled individuals 16 years and older.",
"   </p>",
"   <p>",
"    Cannabis is more commonly used in the United States than any other illicit substance [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/7\">",
"     7",
"    </a>",
"    ]. Large, nationally representative, nonclinical, surveys estimate the cumulative (lifetime) prevalence rate of cannabis use in the general US population is 42 to 46 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. The prevalence rate of cannabis use for the past 12 months is 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    US prevalence rates are associated with specific sociodemographic variables:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age. Both lifetime and annual cannabis use are significantly higher in younger compared to older people [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. As an example, the prevalence of cannabis use in the past year is highest for adults age 18 to 25 years, followed by those 26 to 34 years, 12 to 17 years, 35 to 49 years, and 50 years and older (23 versus 14 versus 9 versus 7 versus 1 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/9\">",
"       9",
"      </a>",
"      ]. Cannabis use rarely occurs before age 13 [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sex. Both lifetime and annual marijuana use are significantly higher in men compared to women. As an example, the prevalence of cannabis use in the past year for men is nearly twice that of women (11.4 versus 6.7 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Race and ethnicity. The annual prevalence of cannabis use is significantly greater for blacks than whites or Hispanics (10.6 versus 8.9 versus 8.6 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/9\">",
"       9",
"      </a>",
"      ]. However, the lifetime prevalence rate is significantly less for Hispanics compared to whites and blacks (odds ratio 0.6) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Education. There is no significant association between educational attainment and lifetime prevalence of cannabis use [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/8\">",
"       8",
"      </a>",
"      ]. However, the annual prevalence rate is significantly less for college graduates compared to those who did not graduate high school (odds ratio 0.8) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Marital status. Lifetime cannabis use is significantly greater in those who are separated or divorced compared to those who are married (odds ratio 1.6) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cannabis dependence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the 46 percent of the US general population that has ever used marijuana, 9 percent also have a lifetime history of dependence. Thus, for every cannabis user who develops dependence, there are 10 users who do not become dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/7\">",
"     7",
"    </a>",
"    ]. Abuse and dependence each develop within a mean of two years (range 0 to 10) after first use [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lifetime prevalence rate of cannabis dependence in the US general population is 1.3 percent, and the 12 month prevalence rate is 0.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/9,11\">",
"     9,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sociodemographic correlates of dependence in the past year are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age. Dependence in the past year is significantly higher for individuals age 12 to 17 years, compared to adults 35 years and older, in a ratio of nearly two to one (OR 1.9) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/9\">",
"       9",
"      </a>",
"      ]. Twelve month prevalence rates for cannabis dependence in those age 21 and 26 years exceed 9 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sex. Dependence in the past year is significantly higher for men compared to women, in a ratio of nearly two to one (OR 1.9) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Education. College educated individuals were significantly less likely to be dependent in the past year compared to those who have not completed high school, in a ratio of two to one (OR 0.5) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Race and ethnicity. Race or ethnicity was not significantly associated with dependence in the past year [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Family income. Income is not significantly associated with dependence in the past year [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Urban residence. There are no significant differences in the rate of dependence in the past year between those residing in urban areas and those in rural areas [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     COMORBID PSYCHOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic studies show that patients with cannabis use disorders frequently suffer from other psychiatric disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Comorbid substance use disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;An Australian epidemiologic study found that adults who use cannabis are significantly more likely to use, abuse, and be dependent upon alcohol, sedatives, stimulants, and opiates, compared to adults who do not use cannabis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A German epidemiologic study prospectively followed a sample aged 14 to 24 years for up to four years. Among those who continuously used cannabis, the prevalence of other substance use was [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alcohol - 90 percent",
"     </li>",
"     <li>",
"      Nicotine - 68 percent",
"     </li>",
"     <li>",
"      Cocaine - 12 percent",
"     </li>",
"     <li>",
"      Stimulants - 9 percent",
"     </li>",
"     <li>",
"      Hallucinogens - 6 percent",
"     </li>",
"     <li>",
"      Opioids - 3 percent",
"     </li>",
"     <li>",
"      Sedatives - 1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An epidemiologic study of US adults found that in the past year, alcohol dependence occurred in 63 percent of those with cannabis dependence and in 41 percent of those with cannabis abuse. In addition, another illicit drug use disorder occurred in 28 percent of those with cannabis dependence and 14 percent of those with cannabis abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cannabis use at an early age is associated with use of other substances at a later age. Support for this association comes from a study that controlled for genetic and shared environmental influences by examining twins discordant for early cannabis use [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/15\">",
"     15",
"    </a>",
"    ]. The twin who used cannabis before age 17, compared to the co-twin who did not, had significantly elevated lifetime rates of cocaine abuse or dependence (OR 4.13, 95% CI 1.91-8.93), opioid abuse or dependence (OR 3.67, 1.02-13.14), and any illicit drug abuse or dependence (OR 2.24, 1.52-3.30). These results are consistent with the gateway theory of drug abuse, which hypothesizes that there is a sequential progression of drug involvement from adolescence into adulthood, starting with tobacco, alcohol, and marijuana, which then leads to the use of other illicit substances [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other comorbid mental illnesses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comorbid mood and anxiety disorders occur frequently in patients with cannabis use disorders. A US epidemiologic study found that mood disorders occur in 61 percent of those with cannabis dependence and 36 percent of those with cannabis abuse. Anxiety disorders occur in 46 percent of those with cannabis dependence and 25 percent of those with cannabis abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/11\">",
"     11",
"    </a>",
"    ]. The most prevalent comorbid disorders are major depressive disorder, mania, specific phobias, and generalized anxiety disorder (",
"    <a class=\"graphic graphic_table graphicRef60041 \" href=\"UTD.htm?9/30/9708\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition, cannabis use occurs more frequently in patients with mental illness compared to the general population. The prevalence of cannabis use disorders among patients with specific illnesses is [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/11,17\">",
"     11,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Schizophrenia - 31 percent",
"     </li>",
"     <li>",
"      Mania - 30 percent",
"     </li>",
"     <li>",
"      Dysthymia - 22 percent",
"     </li>",
"     <li>",
"      Hypomania - 21 percent",
"     </li>",
"     <li>",
"      Major depression - 16 percent",
"     </li>",
"     <li>",
"      Panic disorder with agoraphobia - 26 percent",
"     </li>",
"     <li>",
"      Generalized anxiety disorder - 19 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36521?source=see_link\">",
"     \"Dual diagnosis: Severe mental illness and substance use disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pharmacologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cannabis contains over 400 compounds, including more than 60 cannabinoids. The primary psychoactive cannabinoid is delta-9-tetrahydrocannabinol (THC).",
"   </p>",
"   <p>",
"    After herbal cannabis is smoked, 20 to 50 percent of the THC content is absorbed through the lungs. Oral ingestion results in reduced bioavailability of THC because of hepatic first pass metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nearly all of the absorbed THC binds to protein. THC is widely distributed and accumulates in fatty tissue, from which it is slowly released.",
"   </p>",
"   <p>",
"    THC reaches the brain within minutes following absorption, readily crosses the blood brain barrier, and binds to endogenous, neuronal cannabinoid receptors called CB1. These G protein coupled receptors are distributed throughout the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/2\">",
"     2",
"    </a>",
"    ]. A second receptor, CB2, is present in immune cells and in low levels in the brainstem and possibly other brain regions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    THC activates CB1 receptors in the mesolimbic dopamine system, which is hypothesized to modulate the positive reinforcing and rewarding effects of most drugs of abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/19\">",
"     19",
"    </a>",
"    ]. Abstinence from the drug causes an uncomfortable or distressing withdrawal syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/20\">",
"     20",
"    </a>",
"    ]. The reinforcing properties of THC and the occurrence of a withdrawal syndrome lead to chronic use of cannabis and repeated stimulation of the CB1 receptor, which in turn causes desensitization and down regulation of the receptor, resulting in tolerance to the central nervous system effects [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/18,21\">",
"     18,21",
"    </a>",
"    ]. Other neurotransmitter systems are probably involved as well, including opioid peptides and endogenous cannabinoids [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    THC is metabolized by multiple hepatic isoenzymes. The metabolites are then excreted in urine and feces.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Genetic basis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a substantial degree of heritability of cannabis dependence. A US study found the concordance rate was significantly higher for monozygotic male twins compared to dizygotic male twins (28 versus 9 percent, OR 12, 95% CI 5-31) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    About 60 percent of the likelihood of developing cannabis dependence is due to genetic factors. An Australian twin study found that heritable factors accounted for 67 percent of the variance in the risk of cannabis dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/24\">",
"     24",
"    </a>",
"    ]. Similarly, US twin studies estimate that genetic factors account for 58 percent of the variance in men and 62 percent in women [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/23,25\">",
"     23,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence suggests that cannabis dependence symptoms are linked to regions on chromosomes 3 and 9 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/25\">",
"     25",
"    </a>",
"    ]. Other candidate genes reside on chromosomes 1, 4, 14, and 18 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Psychosocial factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;An Australian twin study found that 20 percent (95% CI 0-44) of the variance in risk of cannabis dependence is accounted for by shared environmental factors and 35 percent (26 to 46 percent) by nonshared environmental factors. Risk factors for developing cannabis dependence include exposure to parental conflict, parental divorce, and childhood sexual abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review found substantial evidence that cannabis is used to cope with stress and relieve tension, especially in heavy users. As an example, 72 percent of daily users in one study used cannabis to relax and relieve tension. Factors such as family dysfunction, negative life events, and abuse can increase stress and the risk of early onset of cannabis use with later addiction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many young adults believe marijuana is relatively harmless [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1079/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, the social context in which cannabis is used plays an important role in the development of addiction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/54/18274?source=see_link\">",
"       \"Patient information: Marijuana use and addiction (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cannabis is the most commonly used illegal substance in the US and in the world. The estimated cumulative (lifetime) incidence of cannabis use among different countries varies from 0.3 to 42.4 percent. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cannabis use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rates of cannabis use are significantly higher in younger individuals and males. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cannabis use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For every cannabis user who develops dependence, there are 10 users who do not become dependent. The lifetime prevalence rate of cannabis dependence in the US general population is 1.3 percent. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Cannabis dependence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with cannabis abuse or cannabis dependence often use other substances, especially alcohol, tobacco, and cocaine. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Comorbid substance use disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Comorbid mood and anxiety disorders occur frequently in patients with cannabis use disorders. The most prevalent comorbid disorders are major depressive disorder, mania, specific phobias, and generalized anxiety disorder. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Other comorbid mental illnesses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cannabis use occurs more frequently in patients with mental illness compared to the general population. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Other comorbid mental illnesses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cannabis dependence appears to be the result of repeated activation of endogenous cannabinoid receptors by delta-9-tetrahydrocannabinol, the primary psychoactive molecule in cannabis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pharmacologic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic factors account for approximately 50 percent of the variance in the risk of cannabis dependence. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Genetic basis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The etiology of cannabis use disorders also involves psychosocial factors, including family dysfunction, negative life events, and childhood sexual abuse. Patients use cannabis to cope with these stressful issues and to relieve tension. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Psychosocial factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1079/abstract/2\">",
"      Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 2001; 178:101.",
"     </a>",
"    </li>",
"    <li>",
"     Hamilton NL, Brantley LB, Tims FM, et al. Family Support Network for Adolescent Cannabis Users, Cannabis Youth Treatment (CYT) Series, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, Rockville, MD 2001. Vol 3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1079/abstract/4\">",
"      Wells DL, Ott CA. The \"new\" marijuana. Ann Pharmacother 2011; 45:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1079/abstract/5\">",
"      Leggett T, United Nations Office on Drugs and Crime. A review of the world cannabis situation. Bull Narc 2006; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1079/abstract/6\">",
"      Degenhardt L, Chiu WT, Sampson N, et al. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: findings from the WHO World Mental Health Surveys. PLoS Med 2008; 5:e141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1079/abstract/7\">",
"      Anthony, JC, Warner, LA, Kessler, RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol 1994; 2:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1079/abstract/8\">",
"      Degenhardt L, Chiu WT, Sampson N, et al. Epidemiological patterns of extra-medical drug use in the United States: evidence from the National Comorbidity Survey Replication, 2001-2003. Drug Alcohol Depend 2007; 90:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1079/abstract/9\">",
"      Kandel D, Chen K, Warner LA, et al. Prevalence and demographic correlates of symptoms of last year dependence on alcohol, nicotine, marijuana and cocaine in the U.S. population. Drug Alcohol Depend 1997; 44:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1079/abstract/10\">",
"      von Sydow K, Lieb R, Pfister H, et al. The natural course of cannabis use, abuse and dependence over four years: a longitudinal community study of adolescents and young adults. Drug Alcohol Depend 2001; 64:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1079/abstract/11\">",
"      Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2006; 67:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1079/abstract/12\">",
"      Poulton R, Moffitt TE, Harrington H, et al. Persistence and perceived consequences of cannabis use and dependence among young adults: implications for policy. N Z Med J 2001; 114:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1079/abstract/13\">",
"      Degenhardt L, Hall W, Lynskey M. The relationship between cannabis use and other substance use in the general population. Drug Alcohol Depend 2001; 64:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1079/abstract/14\">",
"      Grant BF, Pickering R. The relationship between cannabis use and DSM-IV cannabis abuse and dependence: results from the National Longitudinal Alcohol Epidemiologic Survey. J Subst Abuse 1998; 10:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1079/abstract/15\">",
"      Lynskey MT, Heath AC, Bucholz KK, et al. Escalation of drug use in early-onset cannabis users vs co-twin controls. JAMA 2003; 289:427.",
"     </a>",
"    </li>",
"    <li>",
"     Kaminer, Y. Adolescent substance abuse. In: The American Psychiatric Publishing Textbook of Substance Abuse Treatment, 4th ed, Galanter, M, Kleber HD (Ed), American Psychiatric Publishing, Washington, DC 2008. p.527.",
"    </li>",
"    <li>",
"     Ross, S. The mentally ill substance abuser. In: The American Psychiatric Publishing Textbook of Substance Abuse Treatment, 4th ed, Galanter, M, Kleber HD (Eds), American Psychiatric Publishing, Washington, DC 2008. p.540.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1079/abstract/18\">",
"      Clapper JR, Mangieri RA, Piomelli D. The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology 2009; 56 Suppl 1:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1079/abstract/19\">",
"      Cooper ZD, Haney M. Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor. Addict Biol 2008; 13:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1079/abstract/20\">",
"      Hasin DS, Keyes KM, Alderson D, et al. Cannabis withdrawal in the United States: results from NESARC. J Clin Psychiatry 2008; 69:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1079/abstract/21\">",
"      Lichtman AH, Martin BR. Cannabinoid tolerance and dependence. Handb Exp Pharmacol 2005; :691.",
"     </a>",
"    </li>",
"    <li>",
"     Koob, GF. Neurobiology of addiction. In: The American Psychiatric Publishing Textbook of Substance Abuse Treatment, 4th ed, Galanter, M, Kleber HD (Eds), American Psychiatric Publishing, Washington, DC 2008. p.4.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1079/abstract/23\">",
"      Kendler KS, Karkowski LM, Neale MC, Prescott CA. Illicit psychoactive substance use, heavy use, abuse, and dependence in a US population-based sample of male twins. Arch Gen Psychiatry 2000; 57:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1079/abstract/24\">",
"      Sartor, CE, Grant, JD, Bucholz, KK, et al. Common genetic contributions to alcohol and cannabis use and dependence symptomatology. Alcohol Clin Exp Res 2010; 34:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1079/abstract/25\">",
"      Hopfer CJ, Lessem JM, Hartman CA, et al. A genome-wide scan for loci influencing adolescent cannabis dependence symptoms: evidence for linkage on chromosomes 3 and 9. Drug Alcohol Depend 2007; 89:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1079/abstract/26\">",
"      Agrawal A, Lynskey MT. Candidate genes for cannabis use disorders: findings, challenges and directions. Addiction 2009; 104:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1079/abstract/27\">",
"      Lynskey MT, Heath AC, Nelson EC, et al. Genetic and environmental contributions to cannabis dependence in a national young adult twin sample. Psychol Med 2002; 32:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1079/abstract/28\">",
"      Hyman SM, Sinha R. Stress-related factors in cannabis use and misuse: implications for prevention and treatment. J Subst Abuse Treat 2009; 36:400.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7797 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.66.252.144-2A34E2F131-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_3_1079=[""].join("\n");
var outline_f1_3_1079=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H262913216\">",
"      STREET TERMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cannabis use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cannabis dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      COMORBID PSYCHOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Comorbid substance use disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other comorbid mental illnesses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pharmacologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Genetic basis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Psychosocial factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/7797\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/7797|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/51/24380\" title=\"table 1\">",
"      Incidence cannabis use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/30/9708\" title=\"table 2\">",
"      Comorbid mood and anxiety",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=related_link\">",
"      Cancer pain management: Adjuvant analgesics (coanalgesics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21783?source=related_link\">",
"      Cannabis use disorders: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4554?source=related_link\">",
"      Cannabis use disorders: Treatment, prognosis, and long-term medical effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19208?source=related_link\">",
"      Characteristics of antiemetic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36521?source=related_link\">",
"      Dual diagnosis: Severe mental illness and substance use disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/54/18274?source=related_link\">",
"      Patient information: Marijuana use and addiction (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_3_1080="ECG nonsustained ventricular tachycardia";
var content_f1_3_1080=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1095px;\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Nonsustained ventricular tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 127px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nonsustained ventricular tachycardia in a patient with underlying atrial fibrillation. The ventricular arrhythmia consists of nine beats at an approximate rate of 170 beats/min.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_3_1080=[""].join("\n");
var outline_f1_3_1080=null;
var title_f1_3_1081="Drug-eluting compared to bare metal intracoronary stents";
var content_f1_3_1081=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Drug-eluting compared to bare metal intracoronary stents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/3/1081/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/3/1081/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/3/1081/contributors\">",
"     J Dawn Abbott, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/3/1081/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/3/1081/contributors\">",
"     Stephan Windecker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/3/1081/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/3/1081/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/3/1081/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of bare metal stents (BMS) was a major advance over balloon angioplasty in the management of symptomatic coronary artery disease. BMS prevented restenosis by attenuating early arterial recoil and contraction. However, the rate of clinically-indicated target lesion repeat revascularization due to restenosis at one year remains relatively high at 10 to 20 percent of patients and is often due to excessive growth of neointima [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24298?source=see_link&amp;anchor=H2#H2\">",
"     \"Intracoronary stent restenosis\", section on 'Incidence of restenosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drug-eluting stents (DES) were developed to reduce the relatively high rate of restenosis and subsequent repeat revascularization with BMS. Clinical trials have confirmed a reduction of as much as 50 to 70 percent in target lesion revascularization by DES compared to BMS. These findings have led to the preferential use of DES in the majority of percutaneous coronary intervention (PCI). However, as DES require a longer period of dual antiplatelet therapy to prevent stent thrombosis, DES are not appropriate for all patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link&amp;anchor=H18#H18\">",
"     \"Antiplatelet therapy after coronary artery stenting\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the studies that have compared BMS to DES and will make recommendations for the choice of one or the other. The discussions of the various types of DES and coronary artery stent types in development are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/62/16360?source=see_link\">",
"     \"Comparison of drug-eluting intracoronary stents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34773?source=see_link\">",
"     \"Coronary artery stent types in development\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193802422\">",
"    <span class=\"h1\">",
"     CHARACTERISTICS OF DES",
"    </span>",
"    &nbsp;&mdash;&nbsp;DES (",
"    <a class=\"graphic graphic_table graphicRef65603 \" href=\"UTD.htm?11/39/11901\">",
"     table 1",
"    </a>",
"    ) consist of a metallic stent backbone, an antiproliferative drug, and a polymer that serves as the vehicle for the drug and also controls the drug release rate. The drug inhibits excessive growth of neointima, a major cause of restenosis. Since each DES is unique, differences may be observed with respect to deliverability (ease of placement), efficacy (prevention of restenosis), and safety (rates of stent thrombosis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/62/16360?source=see_link\">",
"     \"Comparison of drug-eluting intracoronary stents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348517385\">",
"    <span class=\"h1\">",
"     DES COMPARED TO BMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most studies that evaluated the efficacy or safety of DES compared to BMS, patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    -eluting or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    -eluting stents (SES or PES); these have been called first generation stents. There are few studies comparing second generation everolimus-eluting or zotarolimus-eluting stents (EES or ZES) to BMS. In most studies, DES outperform BMS with regard to the need for repeat revascularization and there is no difference in long-term mortality. The different types of stents are presented in table form (",
"    <a class=\"graphic graphic_table graphicRef65603 \" href=\"UTD.htm?11/39/11901\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Restenosis and the need for target lesion revascularization usually occur within the first year after stent placement; it is within the first year that DES are superior to BMS. Late restenosis (after one year) has been documented with all types of intracoronary stents. The rate is approximately one to two percent per year and is similar between first or second generation DES and BMS [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/4-7\">",
"     4-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348520182\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;High quality evidence of benefit from DES compared to BMS comes from multiple randomized trials and large percutaneous coronary intervention registry data bases. In nearly all settings, DES lower the rate of target lesion revascularization by 50 to 70 percent compared to BMS.",
"   </p>",
"   <p>",
"    A 2007 meta-analysis included 38 randomized trials involving over 18,000 patients with less complex lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/8\">",
"     8",
"    </a>",
"    ]. On-label indications typically included de novo (not restenotic) lesions with a diameter of 2.5 to 3.75 mm and a lesion length less than 28 mm and excluded complex anatomy such as left main disease, occluded vessels, or bifurcation lesions. The three largest studies in the meta-analysis were SIRIUS, TAXUS IV, and TAXUS V, and the duration of follow-up was one to four years. The first generation",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    -eluting or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    -eluting stents (SES or PES) were used in these trials. The principal finding was that there was a significant reduction in target lesion revascularization with both SES and PES compared to BMS (an absolute difference of approximately 12 percent at four years). There was no significant difference in overall mortality between DES and BMS.",
"   </p>",
"   <p>",
"    Similar findings were noted in another meta-analysis and in several large registries [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. The Ontario, Canada coronary intervention database evaluated 3751 propensity matched pairs of patients who received either DES or BMS from 2003 to 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/10\">",
"     10",
"    </a>",
"    ]. The following findings were noted in this registry of patients who likely had more complex lesions than those enrolled in clinical trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At two years, the rate of target vessel revascularization was lower in patients who received DES (7.4 versus 10.7 percent; p &lt;0.001). The benefit was limited to those patients with two or three risk factors for restenosis (diabetes, vessels &lt;3 mm in diameter, and lesions &ge;20 mm in length).",
"      <br/>",
"      <br/>",
"      Other studies have confirmed benefit of DES compared to BMS in patients with larger vessels or shorter lesions, although the absolute difference in benefit is smaller. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=see_link&amp;anchor=H18#H18\">",
"       \"Use of intracoronary stents for specific coronary lesions\", section on 'Large coronary arteries'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=see_link&amp;anchor=H9#H9\">",
"       \"Use of intracoronary stents for specific coronary lesions\", section on 'Long lesions or diffuse disease'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The lower absolute difference in benefit may enter into decision making when choosing between BMS and DES. (See",
"      <a class=\"local\" href=\"#H348519460\">",
"       'When to choose a BMS'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The three-year mortality was significantly lower in the DES group (5.5 versus 7.8 percent), while the rates of myocardial infarction were not significantly different.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following sections on SES, PES, and the second generation EES and ZES highlight the pivotal studies that compared DES to BMS with regard to efficacy. Although the rates of adverse outcomes were reported in some of these, the studies were not powered to detect differences in safety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Sirolimus stents",
"    </span>",
"   </p>",
"   <p>",
"    The benefit of SES in preventing restenosis was documented in the RAVEL, SIRIUS, and SCANDSTENT trials and in the RESEARCH registry:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the RAVEL trial, 238 patients were randomly assigned to an SES or a BMS [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. Entry criteria included stable or unstable angina or silent ischemia as an indication. Patients with complex lesions (eg, with thrombus or substantial calcification) were excluded. The primary endpoint of late luminal loss at six months was significantly lower with the SES (-0.01 mm versus +0.80 mm with the BMS) as was the frequency of restenosis of more than 50 percent of the luminal diameter (0 versus 27 percent). At follow-up of up to one year, the overall rate of adverse cardiac events was significantly lower with the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      stent (6 versus 29 percent); this difference was due primarily to a lower rate of target lesion revascularization (zero versus 23 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The SIRIUS trial compared SES with BMS in 1058 patients with stable or unstable angina and in whom stenting was performed for a newly diagnosed single lesion in a native coronary artery [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/15\">",
"       15",
"      </a>",
"      ]. The coronary disease in this study population was considered complex because there were many long lesions (mean 14.4 mm), small target vessels (mean 2.8 mm), and patients with diabetes (26 percent); 92 percent of lesions were American College of",
"      <span class=\"nowrap\">",
"       Cardiology/American",
"      </span>",
"      Heart Association type B1, B2, or C (",
"      <a class=\"graphic graphic_table graphicRef80401 \" href=\"UTD.htm?26/35/27196\">",
"       table 2",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Nine-month clinical and angiographic follow-up demonstrated a significant benefit of SES compared to BMS with respect to angiographic in-stent restenosis (3 versus 35 percent), late lumen loss (0.17 versus 1.00 mm), and target lesion revascularization (4 versus 17 percent). These benefits were consistent across subgroups, including longer lesions, smaller vessels, and diabetic patients. There was no significant reduction in the clinical end points of death or MI.",
"     </li>",
"     <li>",
"      A report from the RESEARCH registry, which included patients with an acute coronary syndrome or multivessel disease, suggested that the benefit of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      stents is also seen in an unselected clinical population [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/16\">",
"       16",
"      </a>",
"      ]. In this report, 508 patients receiving a sirolimus stent were compared with 450 controls who received a bare metal stent in the immediate period before sirolimus stents became available. At one year, the incidence of target vessel revascularization was significantly reduced with a sirolimus stent (5.1 versus 10.9 percent); the rates of death and MI were not different.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The preceding observations demonstrated the benefit of the SES at one year or less. Longer-term data show that low rates of revascularization events occur in both DES and BMS patients after the first year, but that the benefit of DES is maintained over time. The following observations illustrate the findings with the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    stent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Between one and five years in the SIRIUS trial, there were few new clinical events and the rate of target lesion revascularization at five years remained substantially lower with the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      stent (9.4 versus 24.2 percent with bare metal stents) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/4\">",
"       4",
"      </a>",
"      ]. There were no differences in death, MI, or stent thrombosis between the two groups.",
"     </li>",
"     <li>",
"      In the RAVEL trial, the rate of target lesion revascularization remained significantly lower with the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      stent (11 versus 26 percent) at five years [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The SCANDSTENT trial included 322 patients with symptomatic, complex coronary artery disease (occlusions, bifurcations, ostial lesions, and angulations) who were randomly assigned to PCI with a SES or BMS [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/18\">",
"       18",
"      </a>",
"      ]. At three years, SES were associated with a significantly lower rate of target lesion revascularization (4.9 versus 33.8 percent). There was no significant difference in mortality, but the SES group had significantly fewer myocardial infarctions (6 versus 15).",
"     </li>",
"     <li>",
"      Maintenance of long-term benefit was also seen in the nonrandomized RESEARCH registry in which 508 patients receiving a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      stent were compared with 450 controls who received a bare metal stent in the immediate period before sirolimus stents [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/19\">",
"       19",
"      </a>",
"      ]. The two-year rate of target vessel revascularization remained significantly lower with the sirolimus stent (8.2 versus 14.8 percent). There was no difference in the rate of death or MI (9.7 versus 10.9 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Paclitaxel stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    -eluting stents (PES) compared to BMS for prevention of restenosis was documented in the TAXUS trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The TAXUS II trial included 536 patients with low-risk lesions who were randomly assigned to a BMS or a polymer-based PES with either a slow or moderate drug release rate [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/20\">",
"       20",
"      </a>",
"      ]. At six months, the use of PES was associated with significant reductions in in-stent restenosis (3.5 versus 19.1 percent) and target lesion revascularization (3.9 versus 13.3 percent).",
"     </li>",
"     <li>",
"      The TAXUS IV trial included 1314 patients with a single, previously untreated coronary stenosis were randomly assigned to receive either a slow-release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      -eluting stent or a bare metal stent [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/21\">",
"       21",
"      </a>",
"      ]. At nine months, the paclitaxel stent was associated with reductions in angiographic restenosis (8 versus 27 percent for bare metal stents), late lumen loss (0.39 versus 0.92 mm), and target lesion revascularization (3 versus 11 percent). At one year, these benefits persisted, with a reduction in major adverse cardiac events (10.8 versus 20.0 percent) that was entirely due to a reduction in ischemia-driven target vessel revascularization [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of the TAXUS trials found pooled rates of major adverse cardiac events for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      stents and bare metal stents of 8.7 and 16.7 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Long-term data are more limited with PES than SES. In the TAXUS IV trial, the rate of major adverse cardiovascular events (cardiac death, myocardial infarction, target vessel revascularization, or stent thrombosis) at five years was significantly lower with the slow and moderate drug-eluting stents compared to BMS (24.0 versus 32.8 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348517639\">",
"    <span class=\"h3\">",
"     Everolimus- and zotarolimus-eluting stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Everolimus-and zotarolimus-eluting stents (EES and ZES) are referred to as second generation DES. As the superiority of SES and PES compared to BMS for the end points of restenosis or target lesion revascularization had previously been established, as discussed above, there are few randomized trials comparing second generation DES to BMS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the SPIRIT FIRST (I) trial, the rate of in-stent late lumen loss, one measure of the efficacy of a stent in preventing restenosis, was significantly lower with EES compared to bare-metal stents (0.10 versus 0.87 mm) at six months [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The ENDEAVOR group of trials compared E-ZES to bare metal stents, SES, and PES. In ENDEAVOR II, 1197 patients with single coronary artery stenoses were randomly assigned to either ZES or BMS. The primary end point of target vessel failure (a combination of target vessel revascularization [TVR], recurrent MI, or cardiac death) at nine months occurred significantly less often with ZES (7.9 versus 15.1 percent), with most of the benefit due to a reduction in TVR. This benefit was also found at one and two years [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H374736517\">",
"    <span class=\"h3\">",
"     Efficacy after off-label use",
"    </span>",
"    &nbsp;&mdash;&nbsp;DES lower the rate of stent restenosis in patients with both on- and off-label indications. The studies presented above often enrolled patients with less complex coronary artery anatomy; regulatory agencies approved stents for use in these lesions (on-label indication). Off-label coronary artery stent use occurs when stents are placed in patients with complex anatomy (eg, multilesion PCI, small vessels, large vessels, lesions longer than 30 mm, ostial lesions, restenotic lesions, lesions of the left main, total occlusions, bifurcation lesions, and saphenous vein graft stenosis) and in those with acute myocardial infarction. Off-label use is common, occurring in about 50 percent of patients treated with stents.",
"   </p>",
"   <p>",
"    Large observational studies have demonstrated a lower rate of target vessel revascularization with DES compared to BMS when placed in off-label situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The NHLBI Dynamic registry included 6551 individuals of whom off-label use occurred in 55 percent of patients with a BMS and 49 percent of those with first generation DES [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/26\">",
"       26",
"      </a>",
"      ]. The rate of repeat revascularization was significantly lower in patients treated with DES at one year for either on-label or off-label use (OR 0.53, 95% CI 0.41-0.69 and 0.63 95% CI 0.0.52-0.77, respectively).",
"     </li>",
"     <li>",
"      In a report from of over 90,000 patients in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR), the rates of restenosis at one and two years were significantly lower with newer DES (EES and the Resolute-ZES) than with BMS at one and two years (2.8 versus 6.3 and 3.1 versus 7.4 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/7\">",
"       7",
"      </a>",
"      ]. The rates of target lesion revascularization were also significantly lower with newer DES (2.2 versus 4.6 and 3.1 versus 5.5 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348520471\">",
"    <span class=\"h2\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;When considering the long-term benefits and risk of PCI with stenting, it is useful to be aware of the natural history of patients who undergo PCI, irrespective of the type of stent placed. The best available data on long-term survival after coronary artery stenting come from a 2012 report from the ASCERT study, which linked data from the American College of Cardiology Foundations CathPCI Registry to the Centers for Medicare and Medicaid Services database (United States) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/27\">",
"     27",
"    </a>",
"    ]. This study included nearly 350,000 patients aged &ge;65 years undergoing a first PCI between 2004 and 2007 and the median follow-up was 15 months. Mortality was 3.0, 8.7, 13.4, and 18.7 percent at 30 days and one, two, and three years, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348520735\">",
"    <span class=\"h3\">",
"     Death or MI after DES placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The individual trials comparing BMS to either SES or PES in stable low to moderate risk patients with on-label indications were not powered to detect differences in the rates of total mortality, cardiac mortality, or MI. However, multiple analyses of randomized trials demonstrated no difference between DES and BMS for these end points at up to four years when used for on-label indications [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/28-33\">",
"     28-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A separate question is the relative rate of death and MI with DES and BMS when stenting is performed for both on-label and off-label (ie, higher risk) indications, which represents a more \"real world\" experience. It is estimated that about 55 percent of stents in the United States are placed for off-label use [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/34\">",
"     34",
"    </a>",
"    ]. The rate of either death or MI is higher after stent placement for an off-label indication, irrespective if the stent is a BMS or DES [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/26,34,35\">",
"     26,34,35",
"    </a>",
"    ]. The definition of off-label is presented above. (See",
"    <a class=\"local\" href=\"#H374736517\">",
"     'Efficacy after off-label use'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following are two observational studies demonstrating a higher rate of adverse outcomes in patients receiving DES for off-label indications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The D.E.S.cover registry included 5541 patients in whom a DES had been placed for either on- or off-label (47 percent) indications [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/35\">",
"       35",
"      </a>",
"      ]. At 30 days, the risk of the primary composite end point of death, MI, or stent thrombosis was higher in the off-label group (2.5 versus 1.0 percent). There was no further increase in risk from 30 days to one year. At one year, the rate of target vessel revascularization was significantly higher in the off-label group (7.6 versus 4.4 percent, adjusted HR, 1.49; 95% CI 1.13-1.98).",
"     </li>",
"     <li>",
"      The EVENT registry included 3323 patients in whom a DES had been placed for either on- or off-label (55 percent) indications [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/34\">",
"       34",
"      </a>",
"      ]. At one year, the composite clinical outcome of death, myocardial infarction, or target lesion revascularization occurred significantly more often in the group with off-label indications (15.5 versus 8.9 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many studies have evaluated long-term outcomes in patients treated with either DES or BMS for off-label indications [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/12,36-40\">",
"     12,36-40",
"    </a>",
"    ]. The available data were analyzed in a 2009 meta-analysis of both large observational studies of real world patients comparing BMS and DES (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    - or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    -eluting stents) and randomized trials that enrolled patients with off-label indications [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/33\">",
"     33",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the observational studies of over 130,000 patients, there was a significantly lower rate of death with DES at 2.5 years (hazard ratio [HR] 0.78, 95% CI 0.71-0.86) or MI (HR 0.87, 95% CI0.78-0.97).",
"     </li>",
"     <li>",
"      In the off-label randomized trials of over 4000 patients, there was no significant difference in the rate of either all-cause mortality or MI at 1.5 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Five large observational studies of unrestricted stent use comparing BMS and DES (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    - or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    -eluting stents) have addressed this issue: Three found lower rates of death or MI with DES [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/37-39\">",
"     37-39",
"    </a>",
"    ] and two found equivalent rates [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/12,36\">",
"     12,36",
"    </a>",
"    ]. The following reports are representative findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A report from Swedish Coronary Angiography and Angioplasty Registry (SCAAR), which compared 10,294 patients who received one DES to 18,659 patients who received one BMS (2003 to 2006), found no difference in the combined end point of death or MI or the individual end point of mortality during a mean follow-up of 2.7 years [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/12\">",
"       12",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Analysis by year of enrollment showed a greater number of late events only in those patients enrolled in 2003. An earlier report from SCAAR of patients enrolled in 2003 and 2004 found a significant increase in mortality with DES that began six months after stenting and increased through the three years [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/40\">",
"       40",
"      </a>",
"      ]. This earlier finding may have been attributable at least partly if not primarily to the effects of unmeasured confounding variables with DES being selected for the highest risk patients in this earlier cohort [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/40\">",
"       40",
"      </a>",
"      ]. Another explanation is the likely longer duration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      therapy in later years [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/12\">",
"       12",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A report from SCAAR included 94,384 patients with DES or BMS implantation between 2005 and 2010 [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/7\">",
"       7",
"      </a>",
"      ]. The risk of death at two years was significantly lower with either first or second generation DES compared to BMS (3.4 and 1.9 versus 6.8 percent, respectively).",
"     </li>",
"     <li>",
"      The state of Massachusetts mandated database was used to evaluate all patients who underwent PCI with stenting from April 2003 to September 2004 [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/38\">",
"       38",
"      </a>",
"      ]. From the entire cohort of almost 19,000 individuals, two matched groups of 5549 patients who exclusively received either DES or BMS were compared for two-year risk adjusted mortality and MI. Patients who received DES had significantly lower rates of death from any cause (9.8 versus 12.0 percent) and of MI (8.3 versus 10.3 percent).",
"     </li>",
"     <li>",
"      The Ontario, Canada registry evaluated outcomes in 6944 patients who received either DES or BMS for only off-label indications from 2003 to 2006 [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/37\">",
"       37",
"      </a>",
"      ]. The composite end point of death or MI was significantly lower in the DES group (12.6 versus 14.7 percent) during a median follow-up of two years and was attributable mainly to a significantly lower mortality.",
"     </li>",
"     <li>",
"      In a retrospective cohort of 76,525 Medicare (United States) beneficiaries, receipt of a DES was associated with a significantly lower adjusted mortality compared with either historical (hazard ratio 0.79, 95% CI 0.77-0.81) or contemporary controls (hazard ratio 0.83, 95% CI 0.82-0.86) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each of these observational reports is subject to unmeasured confounding, as there are several reasons for selection of BMS that may be associated with increased risk for mortality, including underlying malignancy, general frailty, etc. We believe that the best interpretation of these studies is that there is no clinically significant difference in the rates of death or MI between DES and BMS when selected for use in patients who are eligible for and likely to comply with appropriate duration of dual anti-platelet therapy. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H374736504\">",
"    <span class=\"h3\">",
"     Stent thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stent thrombosis after placement of any intracoronary stent, while infrequent, almost always leads to MI and often to death. Irrespective of stent type, the risk of stent thrombosis is greatest within the first 30 days after implantation. Compared to BMS, SES and PES have a similar rate of early stent thrombosis, while EES appears to have a lower risk. With regard to very late stent thrombosis, SES and PES appear to have a higher rate, while EES and the Endeavor-ZES appear to have a similar risk. The discussion of the incidence of stent thrombosis is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H4#H4\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Timing and incidence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no convincing evidence that overall rates of stent thrombosis are different for BMS versus DES. Therefore, we believe that the choice between DES and BMS should not be driven to any significant degree by the relative rates of stent thrombosis, but by ability of the patient to comply with recommendations for dual antiplatelet therapy (DAPT) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and a platelet P2Y12 receptor blocker, which is used after stent placement to prevent stent thrombosis. In patients who stop DAPT prematurely, the likelihood of stent thrombosis significantly increases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H11#H11\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Early and late stent thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The minimum required duration of such therapy is one month after BMS and six months after DES (with preference for 12 months if not at high risk for bleeding). In addition, in patients at high risk of bleeding from DAPT, BMS may be a more reasonable choice as the duration of exposure to DAPT will be shorter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348519460\">",
"    <span class=\"h1\">",
"     WHEN TO CHOOSE A BMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to choose a BMS or DES should balance the relative advantages and disadvantages of each. As noted above, DES are associated with a lower rate of target lesion revascularization, but a longer required duration of dual antiplatelet therapy.",
"   </p>",
"   <p>",
"    Circumstances in which implantation of a BMS is appropriate include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients in whom a DES cannot be implanted for technical reasons.",
"     </li>",
"     <li>",
"      Patients for whom compliance with a recommendation for 12 months of dual antiplatelet therapy is likely to be problematic, including those known to have difficulty with medication compliance.",
"     </li>",
"     <li>",
"      Those who are scheduled to undergo surgery requiring cessation of dual antiplatelet therapy in the ensuing year.",
"     </li>",
"     <li>",
"      Those known to be at higher risk of bleeding, including individuals taking an oral anticoagulant. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link&amp;anchor=H2#H2\">",
"       \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Risk factors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We are concerned about implantation of DES in patients for whom medication compliance or early surgery is an issue, as the risk of stent thrombosis is significantly increased in those who prematurely stop dual antiplatelet therapy (in particular the platelet P2Y12 receptor blocker). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link\">",
"     \"Antiplatelet therapy after coronary artery stenting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients in whom the risk of restenosis is very high, or in whom restenosis might lead to a particularly poor outcome will likely derive the greatest benefit from DES. These include those with: left main disease, small vessels, in-stent restenosis, bifurcation lesions, diabetes, long or multiple lesions, or saphenous vein grafts. For patients with a high risk of restenosis who are unlikely to comply with or tolerate 12 months of dual antiplatelet therapy but can receive dual antiplatelet therapy for at least six months, a DES is reasonable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/20/4426?source=see_link&amp;anchor=H2733901#H2733901\">",
"     \"Management of left main coronary artery disease\", section on 'DES versus BMS'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24298?source=see_link&amp;anchor=H20#H20\">",
"     \"Intracoronary stent restenosis\", section on 'Percutaneous coronary intervention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=see_link\">",
"     \"Use of intracoronary stents for specific coronary lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=see_link&amp;anchor=H11#H11\">",
"     \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\", section on 'Stent type'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26538?source=see_link&amp;anchor=H15#H15\">",
"     \"Prevention, presentation, and management of saphenous vein graft stenosis\", section on 'Drug-eluting stents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients for whom there is uncertainty about the ability of the patient to comply with long-term dual antiplatelet therapy, we suggest taking into account the absolute benefit from DES compared to BMS with regard to restenosis and repeat revascularization. For patients in whom the benefit of DES compared to BMS is small, such as those with large coronary arteries (&gt;3.5 mm), and for whom it is uncertain as to their ability to comply with the recommendation for dual antiplatelet therapy, it may be reasonable to choose a BMS.",
"   </p>",
"   <p>",
"    While there may be some difference in the deliverability of one stent compared to another, deliverability should uncommonly be the most important factor when choosing a stent (either BMS or DES).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H374737889\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our recommendations for the choice of the type of intracoronary stent are generally consistent with those made in the 2011 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Society",
"    </span>",
"    for Cardiovascular Angiography and Intervention focused update for percutaneous coronary intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1081/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/10/43170?source=see_link\">",
"       \"Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/38/18020?source=see_link\">",
"       \"Patient information: Heart stents and angioplasty (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The principle factors that determines the choice between drug-eluting stents (DES) and bare metal stents (BMS) are the lower rate of target lesion revascularization with DES and the ability of the patient to comply with a recommendation for dual antiplatelet therapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and a platelet P2Y12 receptor blocker) for 12 months if a DES is placed. For patients with a high risk of restenosis that are at high risk of bleeding, a shorter duration of at least six months of dual antiplatelet therapy can be considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Across a broad range of coronary artery vessel and lesion characteristics, drug-eluting stents (DES) have lower rates of angiographic restenosis and target vessel revascularization compared to bare metal stents (BMS). However, the relative risk of restenosis is not the same for all subsets of patients or lesions. Thus, the potential benefit from DES will be greatest in those situations in which the risk of restenosis is highest. Patients in whom the risk of restenosis is particularly high include those with left main disease, small vessels, in-stent restenosis, bifurcation lesions, diabetes, long or multiple lesions, or saphenous vein grafts. (See",
"      <a class=\"local\" href=\"#H348517385\">",
"       'DES compared to BMS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The minimum required duration of dual antiplatelet therapy is one month for BMS and six months for DES, but 12 months is preferred. The ability of the patient to comply with recommendations for dual antiplatelet therapy needs to be assessed in all patients prior to stent placement. BMS may be preferable in patients who appear to be at risk for medication non-compliance, in whom noncardiac surgery is planned, or for whom the risk of bleeding while on dual antiplatelet therapy is thought to be high. (See",
"      <a class=\"local\" href=\"#H348519460\">",
"       'When to choose a BMS'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The following are our recommendations for the choice between DES and BMS (see",
"      <a class=\"local\" href=\"#H348519460\">",
"       'When to choose a BMS'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients undergoing coronary artery stent placement and who are likely to comply with a recommendation for 12 months of continuous, dual antiplatelet therapy, we recommend DES instead of BMS (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For those patients who are not likely to maintain at least six months of continuous, dual antiplatelet therapy, we recommend implantation of a BMS in preference to a DES (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). These patients might include those for whom medication compliance has been problematic in the past, for whom surgical or invasive procedures are likely in the next six months, or those who appear to be at high bleeding risk.",
"     </li>",
"     <li>",
"      For patients with a high risk of restenosis who can receive at least six months of continuous, dual antiplatelet therapy, we suggest implantation of a DES over a BMS (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In some patients, the ability to comply with a recommendation for dual antiplatelet therapy may be difficult to ascertain. For these patients, it is reasonable to choose a BMS, particularly if the risk of restenosis is relatively low.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23364212\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. David O. Williams for his contributions as a Section Editor to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/1\">",
"      Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/2\">",
"      Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/3\">",
"      Cutlip DE, Chauhan MS, Baim DS, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 2002; 40:2082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/4\">",
"      Weisz G, Leon MB, Holmes DR Jr, et al. Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol 2009; 53:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/5\">",
"      Ellis SG, Stone GW, Cox DA, et al. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). JACC Cardiovasc Interv 2009; 2:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/6\">",
"      Kimura T, Morimoto T, Nakagawa Y, et al. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. Circulation 2012; 125:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/7\">",
"      Sarno G, Lagerqvist B, Fr&ouml;bert O, et al. Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2012; 33:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/8\">",
"      Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007; 370:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/9\">",
"      Hill RA, Boland A, Dickson R, et al. Drug-eluting stents: a systematic review and economic evaluation. Health Technol Assess 2007; 11:iii, xi.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/10\">",
"      Tu JV, Bowen J, Chiu M, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 2007; 357:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/11\">",
"      Abbott JD, Voss MR, Nakamura M, et al. Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: findings from the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol 2007; 50:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/12\">",
"      James SK, Stenestrand U, Lindb&auml;ck J, et al. Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. N Engl J Med 2009; 360:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/13\">",
"      Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/14\">",
"      Serruys PW, Degertekin M, Tanabe K, et al. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation 2002; 106:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/15\">",
"      Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/16\">",
"      Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the \"real world\": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004; 109:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/17\">",
"      Morice MC, Serruys PW, Barragan P, et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol 2007; 50:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/18\">",
"      Kelbaek H, Kl&oslash;vgaard L, Helqvist S, et al. Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial. J Am Coll Cardiol 2008; 51:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/19\">",
"      Ong AT, van Domburg RT, Aoki J, et al. Sirolimus-eluting stents remain superior to bare-metal stents at two years: medium-term results from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol 2006; 47:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/20\">",
"      Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/21\">",
"      Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/22\">",
"      Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004; 109:1942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/23\">",
"      Babapulle MN, Joseph L, B&eacute;lisle P, et al. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004; 364:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/24\">",
"      Serruys PW, Ong AT, Piek JJ, et al. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention 2005; 1:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/25\">",
"      Fajadet J, Wijns W, Laarman GJ, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006; 114:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/26\">",
"      Marroquin OC, Selzer F, Mulukutla SR, et al. A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med 2008; 358:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/27\">",
"      Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Prediction of long-term mortality after percutaneous coronary intervention in older adults: results from the National Cardiovascular Data Registry. Circulation 2012; 125:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/28\">",
"      Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/29\">",
"      Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/30\">",
"      Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/31\">",
"      Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 2006; 27:2784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/32\">",
"      Stone GW, Ellis SG, Colombo A, et al. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation 2007; 115:2842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/33\">",
"      Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009; 119:3198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/34\">",
"      Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007; 297:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/35\">",
"      Beohar N, Davidson CJ, Kip KE, et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 2007; 297:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/36\">",
"      Marzocchi A, Saia F, Piovaccari G, et al. Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. Circulation 2007; 115:3181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/37\">",
"      Ko DT, Chiu M, Guo H, et al. Safety and effectiveness of drug-eluting and bare-metal stents for patients with off- and on-label indications. J Am Coll Cardiol 2009; 53:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/38\">",
"      Mauri L, Silbaugh TS, Wolf RE, et al. Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts. Circulation 2008; 118:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/39\">",
"      Hannan EL, Racz M, Holmes DR, et al. Comparison of coronary artery stenting outcomes in the eras before and after the introduction of drug-eluting stents. Circulation 2008; 117:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/40\">",
"      Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007; 356:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/41\">",
"      Groeneveld PW, Matta MA, Greenhut AP, Yang F. Drug-eluting compared with bare-metal coronary stents among elderly patients. J Am Coll Cardiol 2008; 51:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1081/abstract/42\">",
"      Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58:e44.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1580 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-53F9A3D73A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_3_1081=[""].join("\n");
var outline_f1_3_1081=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H193802422\">",
"      CHARACTERISTICS OF DES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H348517385\">",
"      DES COMPARED TO BMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H348520182\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Sirolimus stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Paclitaxel stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H348517639\">",
"      - Everolimus- and zotarolimus-eluting stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H374736517\">",
"      - Efficacy after off-label use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H348520471\">",
"      Safety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H348520735\">",
"      - Death or MI after DES placement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H374736504\">",
"      - Stent thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H348519460\">",
"      WHEN TO CHOOSE A BMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H374737889\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23364212\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1580\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1580|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/39/11901\" title=\"table 1\">",
"      Coronary artery stents approved in the United States",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/35/27196\" title=\"table 2\">",
"      Lesion-specific characteristics and outcome after balloon angiop",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/62/16360?source=related_link\">",
"      Comparison of drug-eluting intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=related_link\">",
"      Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=related_link\">",
"      Coronary artery stent thrombosis: Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34773?source=related_link\">",
"      Coronary artery stent types in development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24298?source=related_link\">",
"      Intracoronary stent restenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/20/4426?source=related_link\">",
"      Management of left main coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/10/43170?source=related_link\">",
"      Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/38/18020?source=related_link\">",
"      Patient information: Heart stents and angioplasty (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26538?source=related_link\">",
"      Prevention, presentation, and management of saphenous vein graft stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=related_link\">",
"      Use of intracoronary stents for specific coronary lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_3_1082="Echocardiographic evaluation of the aortic valve";
var content_f1_3_1082=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Echocardiographic evaluation of the aortic valve",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/3/1082/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/3/1082/contributors\">",
"     Elyse Foster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/3/1082/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/3/1082/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/3/1082/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/3/1082/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/3/1082/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography is the most effective means of evaluating the aortic valve in normal and diseased states. For most conditions, transthoracic (surface) echocardiography (TTE) is sufficient. Congenital, degenerative, and inflammatory lesions are readily recognized and their severity graded. In addition, it is standard practice for TTE to be the sole method of serial evaluation of aortic stenosis and aortic regurgitation.",
"   </p>",
"   <p>",
"    This topic will review echocardiography of the aortic valve. The diagnosis and management of aortic stenosis and aortic regurgitation are discussed separately in individual topic reviews including the following: (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=see_link\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link\">",
"     \"Indications for valve replacement in aortic stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/62/2025?source=see_link\">",
"     \"Medical management of asymptomatic aortic stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/43/41654?source=see_link\">",
"     \"Medical management of symptomatic aortic stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=see_link\">",
"     \"Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=see_link\">",
"     \"Course and management of chronic aortic regurgitation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ECHOCARDIOGRAPHY OF THE NORMAL AORTIC VALVE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Two-dimensional echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two-dimensional imaging of the normal aortic valve in the parasternal long axis view demonstrates two leaflets (right and noncoronary) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77446 \" href=\"UTD.htm?20/7/20592\">",
"     image 1",
"    </a>",
"    ), while the parasternal short axis demonstrates a symmetrical structure with three uniformly thin leaflets that open equally, forming a circular orifice during most of systole (",
"    <a class=\"graphic graphic_figure graphicRef67673 \" href=\"UTD.htm?12/49/13074\">",
"     figure 1",
"    </a>",
"    ). During diastole, the normal leaflets form a three pointed star with a slight thickening or prominence at the central closing point formed by the aortic leaflet nodules, known as the nodules of Arantius. The three aortic valve cusps may also be visualized in a subcostal view.",
"   </p>",
"   <p>",
"    The aortic valve is composed of three cusps: the left, right, and noncoronary cusps. The left cusp guards the left sinus of Valsalva, with the left main coronary artery arising superior and midway between the commissures of this cusp. The right cusp guards the right sinus of Valsalva, with the right coronary artery arising superiorly. It is the most anterior cusp and is positioned immediately just posterior to the right ventricular outflow tract. Its most rightward commissure is to the septal attachment of the tricuspid valve. The noncoronary cusp is located posteromedially, guards the noncoronary sinus of Valsalva, and sits above the right atrium and interatrial septum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     M-mode echocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;M-mode echocardiography of the aortic valve is performed in conjunction with two-dimensional imaging by targeting the M-mode beam through the aortic leaflets as displayed in the two-dimensional cross sectional view. The M-mode image of a normal aortic valve and root includes a number of distinctive features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the parasternal long axis orientation, the aortic leaflets open and close at the midpoint of the space bounded by the anterior and posterior walls of the aortic root (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79751 \" href=\"UTD.htm?15/54/16228\">",
"       image 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      After the opening motion, the leaflets are parallel to the aortic root and nearly appose its wall, where they remain until the end of systole. The net effect of these features is a \"box-like\" appearance of the M-mode wave form.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Failure of the leaflets to open widely may be seen with aortic stenosis; a decreased stroke volume is suggested if they open widely but drift shut just after achieving maximum separation.",
"     </li>",
"     <li>",
"      If the leaflets close immediately and abruptly after achieving full opening, fixed subvalvular stenosis should be considered. If the leaflets close and reopen in the first third to one half of systole, dynamic subvalvular obstruction should be suspected. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33207?source=see_link\">",
"       \"Subvalvar aortic stenosis (subaortic stenosis)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While in their open systolic position, it is normal for the leaflets to exhibit fine vibrations. The vibrations on the valve have the same timing and frequency of an early systolic low intensity (\"innocent\") murmur.",
"     </li>",
"     <li>",
"      During diastole, the coapted leaflets move parallel to the aortic root.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Vibrations during diastole are highly abnormal and are characteristic of rupture or disruption of the aortic valve.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     OBSTRUCTION TO LEFT VENTRICULAR OUTFLOW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstruction to left ventricular outflow may be due to valvular aortic stenosis, fixed or variable subvalvular stenosis, or supravalvular stenosis. The most common cause is valvular aortic stenosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=see_link\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Valvular aortic stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal aortic valve area in adults is 3.0 to 4.0 cm",
"    <sup>",
"     2",
"    </sup>",
"    . As aortic stenosis develops, minimal valve gradient is present until the orifice area becomes less than half of normal. In general, symptoms in patients with aortic stenosis occur when the valve area is &lt;1.0 cm",
"    <sup>",
"     2",
"    </sup>",
"    or the mean transvalvular gradient exceeds 50 mmHg. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=see_link\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Severe narrowing or obstruction of the aortic valve accompanied by dyspnea, angina, or syncope has a poor prognosis. Surgical (or percutaneous) relief by prosthetic valve or homograft implantation dramatically improves survival in such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link\">",
"     \"Indications for valve replacement in aortic stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Echocardiography in combination with continuous and pulse wave Doppler enables accurate evaluation of aortic stenosis severity. As with almost any application of echocardiography, the major limitations of the technique are dependent on the ability of the sonographer to obtain complete, accurate data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     M-mode echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;M-mode echocardiography remains useful in capturing the motion of the aortic valve; variations in motion patterns are often useful in differentiating severe from mild aortic stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/1\">",
"     1",
"    </a>",
"    ]. In the setting of a trileaflet aortic valve, aortic valve M-mode excursion of at least 12 mm is generally not consistent with severe aortic stenosis.",
"   </p>",
"   <p>",
"    Typically, most aortic stenosis presents on M-mode as dense, persistent echoes replacing the normal motion patterns described above; the echoes may no longer lie parallel to the aorta (",
"    <a class=\"graphic graphic_figure graphicRef77555 \" href=\"UTD.htm?36/54/37735\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Echocardiography of the normal aortic valve'",
"    </a>",
"    above.) Aortic valve sclerosis without stenosis can mimic this pattern; dense echoes from sclerotic areas can obscure normal leaflet motion. Aortic valve sclerosis and stenosis can be differentiated by the two-dimensional Doppler imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Two-dimensional echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two-dimensional echocardiographic findings in aortic stenosis include identification of the number of leaflets, the extent, and pattern of calcification, and the degree and pattern of leaflet motion (",
"    <a class=\"graphic graphic_movie graphicRef59344 \" href=\"UTD.htm?24/5/24660\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef59538 \" href=\"UTD.htm?21/41/22163\">",
"     movie 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef80369 \" href=\"UTD.htm?37/13/38100\">",
"     movie 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef61369 \" href=\"UTD.htm?40/25/41375\">",
"     movie 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef71087 \" href=\"UTD.htm?10/42/10927\">",
"     movie 5",
"    </a>",
"    ). The aortic root (including the aortic ring) is also visualized.",
"   </p>",
"   <p>",
"    There are other findings on the echocardiogram that may help in the assessment of severity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patterns of leaflet motion are helpful, and when leaflets move together in a systolic \"doming\" pattern, the possibility of significant obstruction (or bicuspid valve) is much greater.",
"     </li>",
"     <li>",
"      Two-dimensional imaging can display the aorta distal to the valve, dilatation is often present if significant stenosis is present (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef51528 \" href=\"UTD.htm?7/36/7746\">",
"       image 3",
"      </a>",
"      ). Bicuspid aortic valves are associated with aortopathy and the extent of aortic dilation is not proportional to the severity of stenosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=see_link\">",
"       \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Varying degrees of concentric left ventricular hypertrophy are seen in aortic stenosis. In the well compensated patient with severe aortic stenosis, a resting echocardiogram will generally disclose significant left ventricular hypertrophy with normal or even hyperdynamic contractile function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Doppler echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although observations of two dimensional and M-mode findings are useful in the initial detection of aortic stenosis, Doppler quantitation of transaortic systolic pressure gradient and valve area are definitive diagnostically and are basic to noninvasive evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. In fact, Doppler data are so reliable that diagnostic catheterization for the determination of the severity of aortic stenosis has been relegated to a secondary confirmatory role and for assessment of coexistent coronary artery disease (",
"    <a class=\"graphic graphic_movie graphicRef79119 \" href=\"UTD.htm?43/22/44398\">",
"     movie 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef68228 \" href=\"UTD.htm?32/18/33070\">",
"     movie 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52584 \" href=\"UTD.htm?15/32/15887\">",
"     image 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef73624 \" href=\"UTD.htm?6/20/6479\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef77381 \" href=\"UTD.htm?10/33/10783\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3737?source=see_link\">",
"     \"Hemodynamics of valvular disorders as measured by cardiac catheterization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The critical components of the Doppler examination of aortic stenosis are based on the continuous wave Doppler and include the AS jet velocity, the mean AV gradient, and the AVA derived from the continuity equation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the evaluation of aortic stenosis with Doppler echocardiography, it is essential to employ continuous wave Doppler from a number of sites to sample flow signals arising from the jet across the stenotic aortic orifice so that the highest velocity can be recorded. Only continuous wave Doppler is acceptable because the velocities encountered in all grades of aortic stenosis are too high for pulsed wave Doppler to sample.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3001024\">",
"    <span class=\"h4\">",
"     Peak velocity",
"    </span>",
"    &nbsp;&mdash;&nbsp;To obtain the highest velocity, the angle of interrogation should be as parallel with flow as possible. Since the peak velocity is a function of the cosine of this angle, interrogation angles greater than 30 degrees result in major underestimation of the severity of obstruction. Since it is impossible to predict the orientation that will provide the highest peak velocity, the transaortic valve velocity is interrogated from the apex, suprasternal notch, and right parasternal intercostal spaces. A peak velocity &gt;4",
"    <span class=\"nowrap\">",
"     m/sec",
"    </span>",
"    is strongly suggestive of severe stenosis and clinical outcomes related to stenosis, whereas a peak velocity &lt;3",
"    <span class=\"nowrap\">",
"     m/sec",
"    </span>",
"    usually indicates mild stenosis.",
"   </p>",
"   <p>",
"    Using the highest recorded peak velocity, the simplified Bernoulli equation can be applied to obtain the peak instantaneous gradient:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Peak pressure gradient (mmHg) = 4 &nbsp;x &nbsp;peak velocity(2)",
"   </p>",
"   <p>",
"    It is important to note that the peak instantaneous systolic gradient, as measured by Doppler, may be higher than the \"peak to peak gradient\" obtained during invasive cardiac catheterization. The peak to peak gradient is derived by comparing peak ventricular and aortic pressures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3737?source=see_link\">",
"     \"Hemodynamics of valvular disorders as measured by cardiac catheterization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At times, relatively large peak systolic gradients can be confused with significant aortic obstruction but such confusion can be avoided in three ways.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inspection of the rate of rise of the Doppler wave form. If the wave rises rapidly with a short acceleration time, the stenosis is more likely to be mild, but if it rises more slowly with a long acceleration time, a high gradient is likely to connote severe obstruction (",
"      <a class=\"graphic graphic_figure graphicRef77381 \" href=\"UTD.htm?10/33/10783\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Using the mean gradient across the valve. By planimetry of the continuous wave signal, one can determine the peak velocity and gradient, the mean velocity and gradient, and the velocity time integral (VTI",
"      <sub>",
"       AV",
"      </sub>",
"      ). There is a stronger correlation between mean gradients obtained by echocardiography and near-simultaneous invasive measurements than between the peak instantaneous gradient and the peak to peak gradient.",
"     </li>",
"     <li>",
"      The most effective method of quantitating the severity of aortic stenosis is to calculate the valve area (",
"      <a class=\"graphic graphic_figure graphicRef77899 \" href=\"UTD.htm?30/42/31395\">",
"       figure 4",
"      </a>",
"      ) using the continuity equation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1208?source=see_link\">",
"       \"Aortic valve area in aortic stenosis\"",
"      </a>",
"      .) This calculation is performed by using the continuity principle, which states that in a closed system the flow in one portion of the system is equal to the flow in another [",
"      <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    According to the continuity equation, flow in the left ventricular outflow tract is exactly equal to the flow across the stenotic aortic valve. Simply stated, flow volume (Q) measurements at serial sites in a closed system (such as the heart) should be identical. Planimetry of the pulsed wave Doppler flow signal from the left ventricular outflow tract derives the velocity time integral (VTI), which is the distance the average red blood cell travels during systole in the outflow tract:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Q &nbsp;= &nbsp;Area",
"    <sub>",
"     LVOT",
"    </sub>",
"    &nbsp;x &nbsp;VTI",
"    <sub>",
"     LVOT",
"    </sub>",
"    &nbsp;= &nbsp;AVA &nbsp;x &nbsp;VTI",
"    <sub>",
"     AV",
"    </sub>",
"    <br/>",
"   </p>",
"   <p>",
"    where Area",
"    <sub>",
"     LVOT",
"    </sub>",
"    = cross-sectional area of the LV outflow tract, VTI",
"    <sub>",
"     LVOT",
"    </sub>",
"    = velocity time integral in the outflow tract, AVA = aortic valve area, and VTI",
"    <sub>",
"     AV",
"    </sub>",
"    = velocity time integral across the aortic valve. The effective orifice area of the stenotic valve can therefore be calculated after simple equation rearrangement:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;AVA &nbsp;= &nbsp;(Area",
"    <sub>",
"     LVOT",
"    </sub>",
"    &nbsp;x &nbsp;VTI",
"    <sub>",
"     LVOT",
"    </sub>",
"    ) &nbsp;&divide; &nbsp;VTI",
"    <sub>",
"     AV",
"    </sub>",
"   </p>",
"   <p>",
"    The cross-sectional area of the LVOT is derived from the diameter (d) of the left ventricular outflow tract measured at mid-systole on the parasternal long axis view just proximal to the aortic valve at the hinge-points",
"    <span class=\"nowrap\">",
"     (area=&prod;d",
"     <sup>",
"      2",
"     </sup>",
"     /4).",
"    </span>",
"    The peak velocities in the LVOT and across the AV can be substituted for the respective VTIs in a simplified continuity equation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/7\">",
"     7",
"    </a>",
"    ]. The threshold for severe aortic stenosis is an aortic valve area of 1.0 cm",
"    <sup>",
"     2",
"    </sup>",
"    . In contrast to invasive methods utilizing the Gorlin formula, the continuity equation is relatively insensitive to aortic regurgitation.",
"   </p>",
"   <p>",
"    Other methods of estimating the severity of the aortic stenosis include measurement of aortic valve resistance. Aortic valve resistance (AVR) can be calculated using Doppler echocardiography based upon the following equation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;AVR &nbsp;= &nbsp;[4 (PkV",
"    <sub>",
"     AV",
"    </sub>",
"    )",
"    <sup>",
"     2",
"    </sup>",
"    &nbsp; &divide; &nbsp;( r",
"    <sub>",
"     LVOT",
"    </sub>",
"    <sup>",
"     2",
"    </sup>",
"    x PkV",
"    <sub>",
"     LVOT",
"    </sub>",
"    ) ] x &nbsp;1333",
"    <br/>",
"   </p>",
"   <p>",
"    where PkV",
"    <sub>",
"     AV",
"    </sub>",
"    = peak velocity across the aortic valve, PkV",
"    <sub>",
"     LVOT",
"    </sub>",
"    = peak velocity through the LVOT, and r",
"    <sub>",
"     LVOT",
"    </sub>",
"    is the systolic radius of the LVOT. The cut-off for severe AS is 280",
"    <span class=\"nowrap\">",
"     dynes/s/cm",
"     <sup>",
"      5",
"     </sup>",
"     .",
"    </span>",
"    While aortic valve resistance was initially believed to be less dependent on flow, this claim turns out not to be true. Moreover, resistance is less predictive of prognosis than other measures such as the peak velocity through the valve.",
"   </p>",
"   <p>",
"    The recommended grading for aortic valve stenosis, based on echocardiographic measures, is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef65280 \" href=\"UTD.htm?17/33/17948\">",
"     table 1",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    Aortic stenosis complicated by left ventricular dysfunction with low stroke volume is one cause of low gradient aortic stenosis. Determination of the role of aortic stenosis in this setting is difficult since low stroke volume, on its own, may falsely decrease the calculated valve area by the continuity equation. Identification and evaluation of low gradient aortic stenosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/14/35047?source=see_link\">",
"     \"Low gradient aortic stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Aortic valve sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic valve thickening (sclerosis) without stenosis is common in elderly adults. It is often detected either as a systolic murmur on physical examination or on echocardiography. Aortic valve sclerosis may be important clinically as a marker for increased cardiovascular risk. Aortic and mitral annular calcification frequently accompany aortic sclerosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38279?source=see_link\">",
"     \"Aortic valve sclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of definitions have been used to identify aortic valve sclerosis. A proposed revised definition includes the following criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/9\">",
"     9",
"    </a>",
"    ]: irregular nonuniform thickening of portion of the aortic valve leaflets or commissure, or both; thickened portions of the aortic valve with an appearance (highly echogenic) suggesting calcification, nonrestricted or minimally restricted aortic cusp opening; and transvalvular peak continuous wave Doppler velocity",
"    <span class=\"nowrap\">",
"     &lt;2m/s.",
"    </span>",
"    Tissue harmonic imaging and high gain settings should be avoided when evaluating for aortic sclerosis since these enhancements can accentuate the appearance of leaflet thickening. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Fixed subvalvular stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fixed subvalvular or subaortic stenosis, is a relatively uncommon congenital lesion that is often associated with other cardiovascular abnormalities. Patients with ventricular septal defects (repaired or unrepaired) appear to be at increased risk for acquiring this condition. This disorder should be considered whenever a high velocity jet through the left ventricular outflow tract is identified in the setting of visually mobile aortic leaflets, which often demonstrate early closure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33207?source=see_link\">",
"     \"Subvalvar aortic stenosis (subaortic stenosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most prominent echocardiographic feature of the condition is a linear density crossing the left ventricular outflow tract just proximal to the junction of the aortic root with the septum. On two-dimensional echocardiography, a subvalvular membrane appears to arise from the membranous septum. The degree of obstruction to outflow in subvalvular aortic stenosis cannot be determined by two-dimensional TTE, and Doppler examination is indicated. Color flow Doppler usually demonstrated flow acceleration originating proximal to the aortic valve at the site of obstruction.",
"   </p>",
"   <p>",
"    The picture of fixed subvalvular obstruction may be further obscured and complicated by associated severe asymmetrical septal thickening that extends to just under the fibrous ring, mimicking classic hypertrophic obstructive myopathy. There may also be ectopic mitral chordae attached in and around the narrowed area.",
"   </p>",
"   <p>",
"    It is important to define each of these elements when planning interventional therapy; this task is best accomplished with TEE. When evaluating cases of hypertrophic cardiomyopathy by echocardiography, the possibility of a subvalvular membrane should always be considered. Failure to recognize this condition could lead to inappropriate use of alcohol ablation or a poor surgical result",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Supravalvular aortic stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supravalvular aortic stenosis is rarely seen in adults. When encountered, there is a narrowing directly above and usually affixed to the valve leaflets. Features include aortic regurgitation, enlarged coronary arteries which are sometimes obstructed, and severe hypertrophy. Doppler measurement of the aortic gradient may be useful to distinguish those patients who are candidates for surgical correction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40774?source=see_link\">",
"     \"Supravalvar aortic stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ECHOCARDIOGRAPHIC DIFFERENTIATION AMONG THE CAUSES OF AORTIC STENOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most aortic stenosis presenting in later life is associated with a considerable amount of thickening and calcification in and around the aortic root and valve leaflets. These degenerative changes are nonspecific and do not serve to differentiate among the possible causes of aortic stenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Congenital bicuspid aortic valve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenitally bicuspid aortic valves are common precursors of progressive aortic stenosis and are among the most common congenital cardiac anomalies in the adult. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"    </a>",
"    .) Visualization of three commissures is not sufficient to establish the presence of a trileaflet valve; in most functionally bicuspid valves in adults, three commissures are present but one is fused. The fused commissure can be easily seen echocardiographically and hence the valve may appear tricuspid, especially during diastole. Fusion of the right and left cusps is most common and may be associated with coarctation of the aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/11\">",
"     11",
"    </a>",
"    ]. Less common is fusion of the right and non-coronary cusps followed by the left and non-coronary cusps [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/12\">",
"     12",
"    </a>",
"    ]. Clues to the true nature of these valves include apparent inequality in the size of the leaflets, ovoid opening shape of the orifice, and eccentricity in its position (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70393 \" href=\"UTD.htm?10/42/10912\">",
"     image 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef66664 \" href=\"UTD.htm?21/52/22351\">",
"     movie 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef59607 \" href=\"UTD.htm?27/17/27921\">",
"     movie 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef71102 \" href=\"UTD.htm?40/24/41346\">",
"     movie 10",
"    </a>",
"    ). A true (anatomically) bicuspid valve without a fused commissure is uncommon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Rheumatic aortic stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatic aortic stenosis is a rare cause of aortic stenosis in developed countries and is usually accompanied by significant mitral disease, which dominates the clinical and echocardiographic picture.",
"   </p>",
"   <p>",
"    In general, milder forms of rheumatic aortic valve disease seem to involve the leaflet commissures with very little, if any, involvement of the aortic ring and commissural ring attachments. The thickening and calcification occurs mostly at the edges of the cusps [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Degenerative aortic stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly encountered abnormality associated with aortic stenosis is chronic degeneration of the leaflets that occurs with advanced age. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Aortic valve sclerosis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38279?source=see_link\">",
"     \"Aortic valve sclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With this type of valve disease, the echocardiogram initially demonstrates the greatest concentration of calcification or thickening at the point where the commissures meet the aortic ring.",
"     </li>",
"     <li>",
"      At times, one of the leaflets may become immobile or frozen while the others move freely. When only one leaflet is immobile, there is usually only a mild increase in transaortic velocity (minimal aortic stenosis). The severity of aortic regurgitation in this setting is usually mild.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The natural history of aortic stenosis and risk factors for progression are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30551?source=see_link\">",
"     \"Natural history of aortic stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     AORTIC REGURGITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the mitral, tricuspid, and pulmonic valves, trivial aortic regurgitation is far less common in healthy young adults. As the aortic valve becomes thickened or sclerotic, mild degrees of aortic regurgitation may develop. Pathologic aortic regurgitation may arise from a variety of aortic valve and aortic root abnormalities. It may coexist with aortic stenosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=see_link\">",
"     \"Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20022?source=see_link\">",
"     \"Acute aortic regurgitation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many of these pathologic entities can be identified by echocardiographic imaging and the severity or degree of regurgitation can be measured.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     M-mode echocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diastolic fluttering of the anterior mitral valve leaflet, which occurs when the regurgitant jet is directed posteriorly, was the first M-mode echocardiographic observation permitting the detection of aortic regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/13\">",
"     13",
"    </a>",
"    ]. This sign is less relevant today since Doppler is more accurate for all degrees of aortic regurgitation, including the most trivial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3001368\">",
"    <span class=\"h3\">",
"     Chronic aortic regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In asymptomatic patients with hemodynamically significant aortic regurgitation, it is important to obtain accurate linear measurements of left ventricular dimensions at end-diastole (LVIDd) and end-systole (LVIDs). These measurements can be obtained on the M-mode as long as two-dimensional guidance assures that the beam is perpendicular to the long axis of the ventricle; alternatively, the measurements can be made directly on the two-dimensional image. Indications for aortic valve surgery (including LVIDs and LVIDd thresholds) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=see_link&amp;anchor=H21#H21\">",
"     \"Course and management of chronic aortic regurgitation in adults\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Acute aortic regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of acute severe aortic regurgitation include aortic valve endocarditis, aortic dissection involving the aortic valve and chest",
"    <span class=\"nowrap\">",
"     trauma/deceleration",
"    </span>",
"    injury. Echocardiographic signs of rapid equilibration of aortic and left ventricular diastolic pressures include premature closure of the mitral valve before the onset of the QRS as seen on M-mode. Premature mitral valve closure is a sign indicating that valve closure is caused by an inappropriate rise in left ventricular diastolic pressure due to filling from aortic regurgitation rather than by pressure generated by isovolumic contraction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20022?source=see_link&amp;anchor=H9#H9\">",
"     \"Acute aortic regurgitation in adults\", section on 'Echocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Two dimensional echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two dimensional echocardiogram is important for establishing the etiology and mechanism for the aortic regurgitation (",
"    <a class=\"graphic graphic_movie graphicRef57999 \" href=\"UTD.htm?21/29/21971\">",
"     movie 11",
"    </a>",
"    ). Aortic regurgitation may be due to valvular pathology or aortic root pathology. Important features of the valve include: the number of leaflets, the presence of cusp prolapse, leaflet destruction or perforation, or vegetations interfering with leaflet closure. The aortic root may be dilated due to aorto-annular ectasia, connective tissue disease, or inflammatory disease. In aortic dissection, aortic regurgitation may be due to the intimal flap interfering with cusp closure, root dilation, or loss of valve support with extension of the dissection to the annulus. When TTE is inadequate, TEE may provide additional information.",
"   </p>",
"   <p>",
"    Quantitation of total left ventricular stroke volume from two dimensional echocardiography planimetry of the left ventricle or from the left ventricular outflow tract flow can be compared with the effective forward systemic flow as estimated from transmitral or transpulmonic flow so that regurgitant volume and regurgitant fraction can be calculated from their difference [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/13,15-17\">",
"     13,15-17",
"    </a>",
"    ]. Using the continuity principle, effective regurgitant orifice can also be computed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Doppler echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler echocardiography is the principal method for evaluation of the patient suspected of having aortic regurgitation. Color flow Doppler of the aortic valve from the parasternal long and short axis views is highly sensitive to aortic regurgitation and will demonstrate very mild to severe regurgitation (",
"    <a class=\"graphic graphic_movie graphicRef79578 \" href=\"UTD.htm?9/54/10081\">",
"     movie 12",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef70063 \" href=\"UTD.htm?25/7/25716\">",
"     movie 13",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef76115 \" href=\"UTD.htm?7/27/7604\">",
"     movie 14",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62602 \" href=\"UTD.htm?32/45/33490\">",
"     image 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The width of the vena contracta, the jet width and area, the rate of decay of the continuous wave diastolic velocity (as measured by the pressure half-time), the density of the continuous wave jet, and the duration of reverse flow in the descending aorta are semiquantitative methods of grading the severity of aortic regurgitation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55026 \" href=\"UTD.htm?33/3/33843\">",
"     image 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef52332 \" href=\"UTD.htm?27/5/27733\">",
"     waveform 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Quantitative methods include the effective regurgitant orifice area (EROA) and the regurgitation volume [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/18,20-22\">",
"     18,20-22",
"    </a>",
"    ]. These methods are summarized in the 2003 American Society of Echocardiography (ASE)",
"    <a class=\"external\" href=\"file://www.asefiles.org/vavularregurg.pdf\">",
"     recommendations",
"    </a>",
"    on evaluation of valvular regurgitation. However, a study comparing the EROA and semiquantitative methods (including pressure half-time, diastolic flow reversal, and vena contracta) using standard thresholds found that the vena contracta had good sensitivity and specificity for severe aortic regurgitation but the other methods were specific but less sensitive [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence of aortic and left ventricular diastolic pressure equilibration seen with acute severe aortic regurgitation includes a short aortic regurgitation pressure half-time, a short mitral deceleration time (",
"    <a class=\"graphic graphic_waveform graphicRef52332 \" href=\"UTD.htm?27/5/27733\">",
"     waveform 2",
"    </a>",
"    ), as well as premature closure of the mitral valve as mentioned above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29522073\">",
"    <span class=\"h3\">",
"     Width of the vena contracta",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vena contracta is the narrowest neck of the color flow jet as it passes from the aortic valve and enters the left ventricular outflow tract (receiving chamber). The width of the vena contracta correlates with the severity of aortic regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Mild aortic regurgitation is present when the vena contracta width is less than 0.3 cm and severe regurgitation is present when the vena contracta width is greater than 0.6 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/20\">",
"     20",
"    </a>",
"    ]. This method may be more robust than jet width, particularly in the presence of eccentric jets. In the above cited study comparing vena contracta to effective regurgitant orifice area, a vena contracta &ge; 0.6 cm was 81 percent sensitive and 83 percent specific for severe aortic regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29522080\">",
"    <span class=\"h3\">",
"     Jet width",
"    </span>",
"    &nbsp;&mdash;&nbsp;A related but distinct parameter is the ratio of the jet width to the width of the left ventricular outflow tract. The width of the jet is measured just proximal to (below) the vena contracta within 1 cm of the aortic valve leaflets. A ratio of less than 25 percent is considered mild and 65 percent or greater is considered severe [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/20,24\">",
"     20,24",
"    </a>",
"    ]. A ratio of the cross-sectional area of the jet to the cross-sectional area of the left ventricular outflow tract of &lt;5 percent is categorized as mild and &ge; 60 percent is categorized as severe. The accuracy of jet width and area estimates may be limited when an eccentric jet is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Reversal of aortic flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normally, when flow is sampled in the descending aorta, most flow occurs during ventricular systole and is antegrade. Using magnetic resonance (MR) imaging phase velocity methods, forward flow is seen to stop in the descending aorta during diastole. On pulsed wave Doppler of the descending aorta in normal individuals, there is a small early diastolic reversal of flow that is felt to represent runoff into distal splanchnic beds. In aortic regurgitation, retrograde flow can be detected and its quantity and duration is proportional to the degree of severity of the lesion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55026 \" href=\"UTD.htm?33/3/33843\">",
"     image 7",
"    </a>",
"    ). The retrograde flow signal may become holodiastolic and the velocity time integral of retrograde diastolic flow may approach that of systolic flow.",
"   </p>",
"   <p>",
"    There are several pitfalls in using this sign for evaluating AR severity. Diastolic flow reversal may become more prominent with decreases in aortic compliance as occurs with normal aging. Diastolic flow reversal in the descending thoracic aorta may also be due to an upper extremity arteriovenous fistula for dialysis or a cerebral arteriovenous malformation. In the above cited study comparing diastolic flow reversal to effective regurgitant orifice area, a diastolic flow reversal &ge;18",
"    <span class=\"nowrap\">",
"     cm/sec",
"    </span>",
"    was 45 percent sensitive and 87 percent specific for severe aortic regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/23\">",
"     23",
"    </a>",
"    ]. Thus, the presence of this finding must be integrated with other measures of AR severity.",
"   </p>",
"   <p>",
"    In the quantitative application of relative antegrade and retrograde flows, one must also account for changes in aortic diameter which must be measured in diastole and systole [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Continuous wave Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous wave Doppler of the regurgitant jet acquired from the apical five chamber or apical three long axis can be used to qualitatively grade the severity of aortic regurgitation (",
"    <a class=\"graphic graphic_figure graphicRef53257 \" href=\"UTD.htm?37/25/38288\">",
"     figure 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef63455 \" href=\"UTD.htm?43/41/44703\">",
"     waveform 3",
"    </a>",
"    ). The flow signal velocity is determined throughout diastole by the gradient between the aortic root and the left ventricle. Ordinarily, the diastolic pressure in the left ventricle is much lower than the aortic root pressure (12 versus 80 mmHg). Thus, the velocity of the aortic regurgitation jet at early diastole is generally at least 4",
"    <span class=\"nowrap\">",
"     m/sec",
"    </span>",
"    and subsequently slowly declines. In mild regurgitation, the deceleration time for that decline usually exceeds 500 msec. In severe aortic regurgitation, the pressure gradient between aortic root and left ventricle becomes very small because the diastolic systemic pressure falls and the left ventricle pressure rises. As the gradient is abolished, the retrograde flow ceases and the velocity of the diastolic signal falls towards zero. The more rapidly the signal decays, the more severe the regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/26\">",
"     26",
"    </a>",
"    ]. A deceleration time of less than 200 msec or a decay slope greater than 3",
"    <span class=\"nowrap\">",
"     m/sec",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    is indicative of severe aortic regurgitation.",
"   </p>",
"   <p>",
"    However, the pressure half-time has limited sensitivity for detection of severe aortic regurgitation, particularly in the chronic setting. In the above cited study comparing pressure half time to effective regurgitant orifice area, a pressure half time &lt;200 msec was 12 percent sensitive and 100 percent specific for severe aortic regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pressure half-time can be confounded in situations such as severe heart failure, where the filling pressure in the left ventricle is elevated and mean aortic pressure reduced. It can also be influenced by changes in systemic vascular resistance and left ventricular compliance. Increasing the systemic vascular resistance increases the rate of decay without any change in valve orifice; reduced left ventricular compliance produces a more rapid rise in left ventricular pressure, which influences the diastolic slope without reflecting the severity of aortic regurgitation. In patients with compensated chronic severe aortic regurgitation, the dilated ventricle may have near normal filling pressures and the rate of diastolic velocity decline is often intermediate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Severity of aortic regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe aortic regurgitation is considered to be present if one or more of the following findings are present on echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/20,27\">",
"     20,27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A regurgitant fraction &ge;50 percent",
"     </li>",
"     <li>",
"      A vena contracta width &gt;6 mm",
"     </li>",
"     <li>",
"      A regurgitant volume &ge;60 mL",
"     </li>",
"     <li>",
"      Central jet width &ge;65 percent of left ventricular outflow tract",
"     </li>",
"     <li>",
"      An effective regurgitant orifice area &ge;0.30 cm",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The European Association of Echocardiography guidelines particularly emphasize assessment of the vena contracta and quantitative measures including the regurgitant volume and effective regurgitant orifice area [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=see_link\">",
"     \"Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Echocardiography and the timing of surgery for aortic regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of echocardiography in the timing of surgery for aortic regurgitation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=see_link\">",
"     \"Course and management of chronic aortic regurgitation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     ECHOCARDIOGRAPHIC DETERMINATION OF THE ETIOLOGY OF AORTIC REGURGITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any process that interferes with the integrity of the aortic valve leaflets can result in aortic incompetence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=see_link\">",
"     \"Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3341089\">",
"    <span class=\"h2\">",
"     Aortic root disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic root dilatation is a common cause of aortic regurgitation. Aortic root dilation is often idiopathic. Causes of aortic root dilation include dilation associated with bicuspid aortic valve, Marfan syndrome, sinus of Valsalva aneurysm (with and without fistulous connection), annuloaortic ectasia, luetic aortitis, and aortic root dilation in association with ankylosing spondylitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/9/151?source=see_link\">",
"     \"Clinical manifestations of ankylosing spondylitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12150?source=see_link\">",
"     \"Pathophysiology, transmission, and natural history of syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The echocardiographic findings in these various conditions can be nonspecific, and differentiation must rest on clinical or pathological grounds. Dilation of the aortic root and thickening of its walls are, however, common echocardiographic findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3341190\">",
"    <span class=\"h3\">",
"     Marfan syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Marfan syndrome is also associated with mitral prolapse and aortic regurgitation. Although this condition appears allied with mitral valve prolapse, the appearance of the aortic valve and root are distinctly different (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50641 \" href=\"UTD.htm?32/38/33378\">",
"     image 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54727 \" href=\"UTD.htm?36/30/37344\">",
"     image 9",
"    </a>",
"    ). In the Marfan patient, isolated dilation of the sinuses of Valsalva with sparing of the ascending aorta and a non-prolapsing aortic valve is typical, although diffuse fusiform dilatation may be present. [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link\">",
"     \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3341197\">",
"    <span class=\"h3\">",
"     Aortic dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dissection of the proximal aorta is a major cause of acute severe aortic regurgitation. TEE, computed tomography, and magnetic resonance imaging are the methods of choice for the emergency diagnosis of aortic dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. By TTE, the intimal flap can be very difficult to image, but some degree of root dilation is usually present. Some studies have suggested that the sensitivity of TTE for detecting an aortic dissection is in the range of 65 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3341204\">",
"    <span class=\"h3\">",
"     Sinus of Valsalva aneurysm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus of Valsalva aneurysm, a form of aortic root aneurysm, is characterized by asymmetric dilation involving one of the sinuses. The dilated sinus will often bulge in systole, facilitating detection. In the setting of a sinus of Valsalva aneurysm, a Doppler examination should be performed and both aortic regurgitation and an intracardiac communication at the site of the aneurysm sought.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Bicuspid aortic valve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic regurgitation commonly arises in non-stenotic bicuspid aortic valves. These valves can often be recognized by two dimensional imaging of the aorta in the precordial short axis view (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70393 \" href=\"UTD.htm?10/42/10912\">",
"     image 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef66664 \" href=\"UTD.htm?21/52/22351\">",
"     movie 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef59607 \" href=\"UTD.htm?27/17/27921\">",
"     movie 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef71102 \" href=\"UTD.htm?40/24/41346\">",
"     movie 10",
"    </a>",
"    ). The mechanism for aortic regurgitation in the setting of bicuspid aortic valve may be due to associated aortic root dilatation, endocarditis, or cusp prolapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3341065\">",
"    <span class=\"h2\">",
"     Rheumatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic regurgitation in association with rheumatic mitral involvement can be readily appreciated by Doppler echocardiography. In this setting, the aortic valve leaflet edges are thickened along their entire border and the aortic ring is small and normal in appearance. While this type of aortic regurgitation is often mild, it can occasionally be moderate or even severe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endocarditis of the aortic valve is a leading cause of acute severe aortic regurgitation. Classically, dense mobile echoes prolapsing into the left ventricular outflow tract are diagnostic when present. However, approximately 25 percent of patients with clinically diagnosed infective endocarditis have no vegetations detected by TTE. The presence of a pre-existing abnormality serving as a nidus for infection, especially if calcified, can make vegetation detection difficult by transthoracic echocardiography (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62352 \" href=\"UTD.htm?5/7/5232\">",
"     image 10",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53904 \" href=\"UTD.htm?17/0/17411\">",
"     image 11",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef52651 \" href=\"UTD.htm?30/9/30867\">",
"     movie 15",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef55154 \" href=\"UTD.htm?21/47/22260\">",
"     movie 16",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef79209 \" href=\"UTD.htm?21/28/21954\">",
"     movie 17",
"    </a>",
"    ). TEE, with its superior resolution, has greatly improved the detection rate of vegetations of the aortic valve [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Secondary involvement of the mitral valve in patients with primary aortic valve endocarditis has been demonstrated on TEE in 10 percent of patients. This can arise from large aortic vegetations (&gt;6 mm) that prolapse into the left ventricle during diastole and contact the anterior mitral leaflet, causing it to be secondarily infected (mitral kissing vegetation) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/3/1082/abstract/33\">",
"     33",
"    </a>",
"    ]. Mitral valve involvement can also result from direct extension of cellulitis through the continuous central fibrous body.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Subaortic stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic regurgitation can arise in association with jet lesions from subaortic stenosis. In this situation, dynamic or fixed outflow tract narrowing produces a jet of high velocity blood that strikes the aortic valve. The resulting damage may alter the valve architecture and produce aortic regurgitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33207?source=see_link\">",
"     \"Subvalvar aortic stenosis (subaortic stenosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Myxomatous disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic regurgitation in association with mitral valve prolapse can be due either to myxomatous changes in the leaflets themselves or to aortic root disease. Although uncommon, aortic valve prolapse due to myxomatous degeneration can be seen in association with mitral prolapse.",
"   </p>",
"   <p>",
"    The most common manifestation of aortic root disease is general dilatation of the sinuses. Dilatation limited to one sinus is called a sinus of Valsalva aneurysm, which is a form of aortic root aneurysm. (See",
"    <a class=\"local\" href=\"#H3341204\">",
"     'Sinus of Valsalva aneurysm'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3340925\">",
"    <span class=\"h2\">",
"     Aortic valve sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, aortic valve sclerosis is a degenerative process that may progress to aortic stenosis. When aortic regurgitation is present, it is usually mild. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38279?source=see_link\">",
"     \"Aortic valve sclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Rheumatoid arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, aortic regurgitation can arise from a rheumatoid nodule on the valve. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=see_link\">",
"     \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Leaflet fenestrations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leaflet fenestrations are said to be common among post mortem specimens. They can be inferred by color flow Doppler detection of an unusual site of regurgitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Ventricular septal defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small ventricular septal defects in the perimembranous region frequently close during childhood. They can be associated with aortic regurgitation that can persist after closure. Doubly committed subarterial ventricular septal defects (also called supracristal ventricular septal defects) are also associated with aortic regurgitation and are more likely to be associated with hemodynamically significant aortic regurgitation due to undermining of the right coronary cusp, resulting in prolapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32389361\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The left, right, and noncoronary cusps of the aortic valve are visualized by transthoracic echocardiography in the parasternal short-axis view (as well as in a subcostal short-axis view): the left cusp is adjacent to the main pulmonary artery, the right cusp is adjacent to the right ventricular outflow track, and the noncoronary cusp is adjacent to the interatrial septum.",
"     </li>",
"     <li>",
"      Aortic valve motion can be visualized in M-mode and two-dimensional views. Failure of the leaflets to open widely may be seen with aortic stenosis; a decreased stroke volume is suggested if they open widely but drift shut just after achieving maximum separation.",
"     </li>",
"     <li>",
"      Transesophageal echocardiography may be required in some patients to distinguish valvular stenosis from subvalvular or supravalvular obstruction. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Obstruction to left ventricular outflow'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Doppler echocardiography enables quantification of aortic valve gradients. The continuity equation can be used to calculate aortic valve area (",
"      <a class=\"graphic graphic_figure graphicRef77899 \" href=\"UTD.htm?30/42/31395\">",
"       figure 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Doppler echocardiography'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1208?source=see_link&amp;anchor=H6#H6\">",
"       \"Aortic valve area in aortic stenosis\", section on 'Echocardiography'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When aortic regurgitation is acute and severe (often due to active aortic valve endocarditis, aortic dissection involving the aortic valve, or chest",
"      <span class=\"nowrap\">",
"       trauma/deceleration",
"      </span>",
"      injury), M-mode is of value in detecting premature closure of the mitral valve, which is defined as valve closure that occurs on or before the onset of the QRS and indicates that the valve did not close because of isovolumic contraction but rather because of an inappropriate rise in left ventricular pressure due to filling from aortic regurgitation.",
"     </li>",
"     <li>",
"      Assessment of aortic regurgitation requires an integrative approach including the width of the vena contracta, the rate of decay of the continuous wave diastolic velocity (pressure half-time), the density of the continuous wave jet, the degree of reverse flow in the descending aorta, as well as the presence of LV enlargement and hypertrophy (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef55026 \" href=\"UTD.htm?33/3/33843\">",
"       image 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In asymptomatic patients with chronic severe aortic regurgitation, echocardiography is used to determine whether left ventricular dilatation and left ventricular dysfunction meet criteria for aortic valve replacement. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=see_link&amp;anchor=H20#H20\">",
"       \"Course and management of chronic aortic regurgitation in adults\", section on 'Aortic valve replacement or repair'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Echocardiography enables determination of the cause of aortic regurgitation. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Echocardiographic determination of the etiology of aortic regurgitation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/1\">",
"      Chin ML, Bernstein RF, Child JS, Krivokapich J. Aortic valve systolic flutter as a screening test for severe aortic stenosis. Am J Cardiol 1983; 51:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/2\">",
"      Godley RW, Green D, Dillon JC, et al. Reliability of two-dimensional echocardiography in assessing the severity of valvular aortic stenosis. Chest 1981; 79:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/3\">",
"      Stoddard MF, Hammons RT, Longaker RA. Doppler transesophageal echocardiographic determination of aortic valve area in adults with aortic stenosis. Am Heart J 1996; 132:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/4\">",
"      Teirstein P, Yeager M, Yock PG, Popp RL. Doppler echocardiographic measurement of aortic valve area in aortic stenosis: a noninvasive application of the Gorlin formula. J Am Coll Cardiol 1986; 8:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/5\">",
"      Yeager M, Yock PG, Popp RL. Comparison of Doppler-derived pressure gradient to that determined at cardiac catheterization in adults with aortic valve stenosis: implications for management. Am J Cardiol 1986; 57:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/6\">",
"      Otto CM. Valvular aortic stenosis: disease severity and timing of intervention. J Am Coll Cardiol 2006; 47:2141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/7\">",
"      Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr 2009; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/8\">",
"      Baumgartner H, Kratzer H, Helmreich G, Kuehn P. Determination of aortic valve area by Doppler echocardiography using the continuity equation: a critical evaluation. Cardiology 1990; 77:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/9\">",
"      Gharacholou SM, Karon BL, Shub C, Pellikka PA. Aortic valve sclerosis and clinical outcomes: moving toward a definition. Am J Med 2011; 124:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/10\">",
"      Tani LY, Minich LL, Pagotto LT, Shaddy RE. Usefulness of doppler echocardiography to determine the timing of surgery for supravalvar aortic stenosis. Am J Cardiol 2000; 86:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/11\">",
"      Siu SC, Silversides CK. Bicuspid aortic valve disease. J Am Coll Cardiol 2010; 55:2789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/12\">",
"      Sievers HH, Schmidtke C. A classification system for the bicuspid aortic valve from 304 surgical specimens. J Thorac Cardiovasc Surg 2007; 133:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/13\">",
"      Landzberg JS, Pflugfelder PW, Cassidy MM, et al. Etiology of the Austin Flint murmur. J Am Coll Cardiol 1992; 20:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/14\">",
"      Botvinick EH, Schiller NB, Wickramasekaran R, et al. Echocardiographic demonstration of early mitral valve closure in severe aortic insufficiency. Its clinical implications. Circulation 1975; 51:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/15\">",
"      Blumlein S, Bouchard A, Schiller NB, et al. Quantitation of mitral regurgitation by Doppler echocardiography. Circulation 1986; 74:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/16\">",
"      Sechtem U, Pflugfelder PW, Cassidy MM, et al. Mitral or aortic regurgitation: quantification of regurgitant volumes with cine MR imaging. Radiology 1988; 167:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/17\">",
"      Pflugfelder PW, Landzberg JS, Cassidy MM, et al. Comparison of cine MR imaging with Doppler echocardiography for the evaluation of aortic regurgitation. AJR Am J Roentgenol 1989; 152:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/18\">",
"      Tribouilloy CM, Enriquez-Sarano M, Fett SL, et al. Application of the proximal flow convergence method to calculate the effective regurgitant orifice area in aortic regurgitation. J Am Coll Cardiol 1998; 32:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/19\">",
"      Tribouilloy CM, Enriquez-Sarano M, Bailey KR, et al. Assessment of severity of aortic regurgitation using the width of the vena contracta: A clinical color Doppler imaging study. Circulation 2000; 102:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/20\">",
"      Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003; 16:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/21\">",
"      Lancellotti P, Tribouilloy C, Hagendorff A, et al. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 1: aortic and pulmonary regurgitation (native valve disease). Eur J Echocardiogr 2010; 11:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/22\">",
"      Pouleur AC, le Polain de Waroux JB, Goffinet C, et al. Accuracy of the flow convergence method for quantification of aortic regurgitation in patients with central versus eccentric jets. Am J Cardiol 2008; 102:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/23\">",
"      Messika-Zeitoun D, Detaint D, Leye M, et al. Comparison of semiquantitative and quantitative assessment of severity of aortic regurgitation: clinical implications. J Am Soc Echocardiogr 2011; 24:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/24\">",
"      Perry GJ, Helmcke F, Nanda NC, et al. Evaluation of aortic insufficiency by Doppler color flow mapping. J Am Coll Cardiol 1987; 9:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/25\">",
"      Touche T, Prasquier R, Nitenberg A, et al. Assessment and follow-up of patients with aortic regurgitation by an updated Doppler echocardiographic measurement of the regurgitant fraction in the aortic arch. Circulation 1985; 72:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/26\">",
"      Teague SM, Heinsimer JA, Anderson JL, et al. Quantification of aortic regurgitation utilizing continuous wave Doppler ultrasound. J Am Coll Cardiol 1986; 8:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/27\">",
"      Bekeredjian R, Grayburn PA. Valvular heart disease: aortic regurgitation. Circulation 2005; 112:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/28\">",
"      Freed C, Schiller NB. Echocardiographic findings in Marfan's syndrome. West J Med 1977; 126:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/29\">",
"      Foster E, Schiller NB. The role of transesophageal echocardiography in critical care: UCSF experience. J Am Soc Echocardiogr 1992; 5:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/30\">",
"      Khandheria BK, Seward JB, Tajik AJ. Transesophageal echocardiography. Mayo Clin Proc 1994; 69:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/31\">",
"      Pavlides GS, Hauser AM, Stewart JR, et al. Contribution of transesophageal echocardiography to patient diagnosis and treatment: a prospective analysis. Am Heart J 1990; 120:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/32\">",
"      Grayburn PA, Handshoe R, Smith MD, et al. Quantitative assessment of the hemodynamic consequences of aortic regurgitation by means of continuous wave Doppler recordings. J Am Coll Cardiol 1987; 10:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/3/1082/abstract/33\">",
"      Piper C, Hetzer R, K&ouml;rfer R, et al. The importance of secondary mitral valve involvement in primary aortic valve endocarditis; the mitral kissing vegetation. Eur Heart J 2002; 23:79.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5295 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6D34BE7A96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_3_1082=[""].join("\n");
var outline_f1_3_1082=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32389361\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ECHOCARDIOGRAPHY OF THE NORMAL AORTIC VALVE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Two-dimensional echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      M-mode echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      OBSTRUCTION TO LEFT VENTRICULAR OUTFLOW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Valvular aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - M-mode echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Two-dimensional echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Doppler echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3001024\">",
"      Peak velocity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Aortic valve sclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Fixed subvalvular stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Supravalvular aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ECHOCARDIOGRAPHIC DIFFERENTIATION AMONG THE CAUSES OF AORTIC STENOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Congenital bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Rheumatic aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Degenerative aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      AORTIC REGURGITATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      M-mode echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3001368\">",
"      - Chronic aortic regurgitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Acute aortic regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Two dimensional echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Doppler echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29522073\">",
"      - Width of the vena contracta",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29522080\">",
"      - Jet width",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Reversal of aortic flow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Continuous wave Doppler",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Severity of aortic regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Echocardiography and the timing of surgery for aortic regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      ECHOCARDIOGRAPHIC DETERMINATION OF THE ETIOLOGY OF AORTIC REGURGITATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3341089\">",
"      Aortic root disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3341190\">",
"      - Marfan syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3341197\">",
"      - Aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3341204\">",
"      - Sinus of Valsalva aneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3341065\">",
"      Rheumatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Subaortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Myxomatous disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3340925\">",
"      Aortic valve sclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Leaflet fenestrations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Ventricular septal defect",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32389361\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5295\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5295|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/7/20592\" title=\"diagnostic image 1\">",
"      2D TTE parasternal long axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/54/16228\" title=\"diagnostic image 2\">",
"      2D TEE and M mode images parasternal short axis aortic valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/36/7746\" title=\"diagnostic image 3\">",
"      Long axis poststenotic dilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/32/15887\" title=\"diagnostic image 4\">",
"      CW Doppler AS severe",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/42/10912\" title=\"diagnostic image 5\">",
"      M mode bicuspid AV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/45/33490\" title=\"diagnostic image 6\">",
"      Color flow Doppler moderate AR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/3/33843\" title=\"diagnostic image 7\">",
"      Abdomen aorta flow reversal AR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/38/33378\" title=\"diagnostic image 8\">",
"      Aortic root enlargement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/30/37344\" title=\"diagnostic image 9\">",
"      Long axis aortic root dilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/7/5232\" title=\"diagnostic image 10\">",
"      Parasternal long axis echo aortic valve vegetations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/0/17411\" title=\"diagnostic image 11\">",
"      Parasternal echo aortic valve vegetations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5295|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/49/13074\" title=\"figure 1\">",
"      2D TTE parasternal short axis view aortic root",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/54/37735\" title=\"figure 2\">",
"      M mode aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/33/10783\" title=\"figure 3\">",
"      Doppler jet patterns AS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/42/31395\" title=\"figure 4\">",
"      Calculation valve area AS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/25/38288\" title=\"figure 5\">",
"      Aortic regurgitation CW Doppler",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5295|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?24/5/24660\" title=\"movie 1\">",
"      Echocardiogram PLAX view of calcific AS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?21/41/22163\" title=\"movie 2\">",
"      Echocardiogram apical long axis view of calcific aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?37/13/38100\" title=\"movie 3\">",
"      Echocardiogram five chamber view of AS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?40/25/41375\" title=\"movie 4\">",
"      Echocardiogram 5 chamber magnified view of AS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?10/42/10927\" title=\"movie 5\">",
"      Aortic stenosis short axis echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?43/22/44398\" title=\"movie 6\">",
"      Aortic stenosis continuous wave doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?32/18/33070\" title=\"movie 7\">",
"      Calcific aortic stenosis color doppler echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?21/52/22351\" title=\"movie 8\">",
"      M-mode echocardiogram of AR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?27/17/27921\" title=\"movie 9\">",
"      Bicuspid aortic valve short axis echocardiogram 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?40/24/41346\" title=\"movie 10\">",
"      Bicuspid aortic valve short axis echocardiogram 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?21/29/21971\" title=\"movie 11\">",
"      Aortic regurgitation long axis echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?9/54/10081\" title=\"movie 12\">",
"      Aortic regurgitation five chamber color Doppler echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?25/7/25716\" title=\"movie 13\">",
"      Apical 5 chamber echo with color Doppler AR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?7/27/7604\" title=\"movie 14\">",
"      Parasternal long axis color Doppler echo AR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?30/9/30867\" title=\"movie 15\">",
"      Parasternal long axis echo aortic valve vegetation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?21/47/22260\" title=\"movie 16\">",
"      Aortic valve endocarditis long axis color Doppler echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?21/28/21954\" title=\"movie 17\">",
"      Parasternal long axis echo close up aortic valve vegetation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5295|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/33/17948\" title=\"table 1\">",
"      Severity of AS in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5295|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?6/20/6479\" title=\"waveform 1\">",
"      CW Doppler AS mild",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?27/5/27733\" title=\"waveform 2\">",
"      Doppler mitral inflow AR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?43/41/44703\" title=\"waveform 3\">",
"      Continuous wave Doppler AR",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20022?source=related_link\">",
"      Acute aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1208?source=related_link\">",
"      Aortic valve area in aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38279?source=related_link\">",
"      Aortic valve sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=related_link\">",
"      Clinical features and evaluation of aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=related_link\">",
"      Clinical manifestations and diagnosis of bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/9/151?source=related_link\">",
"      Clinical manifestations of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=related_link\">",
"      Course and management of chronic aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=related_link\">",
"      Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3737?source=related_link\">",
"      Hemodynamics of valvular disorders as measured by cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=related_link\">",
"      Indications for valve replacement in aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/14/35047?source=related_link\">",
"      Low gradient aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/62/2025?source=related_link\">",
"      Medical management of asymptomatic aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/43/41654?source=related_link\">",
"      Medical management of symptomatic aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30551?source=related_link\">",
"      Natural history of aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=related_link\">",
"      Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=related_link\">",
"      Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12150?source=related_link\">",
"      Pathophysiology, transmission, and natural history of syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33207?source=related_link\">",
"      Subvalvar aortic stenosis (subaortic stenosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40774?source=related_link\">",
"      Supravalvar aortic stenosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_3_1083="Disorders impaired language";
var content_f1_3_1083=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions associated with language impairment in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Intellectual disability (mental retardation)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Learning disabilities",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Attention deficit hyperactivity disorder",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Autism/pervasive developmental disorder",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Traumatic brain injury",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hearing loss",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neglect/abuse",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_3_1083=[""].join("\n");
var outline_f1_3_1083=null;
var title_f1_3_1084="Examples of oxytocin infusion protocols";
var content_f1_3_1084=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examples of oxytocin infusion protocols",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Regimen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Starting dose milliunits/minute",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incremental increase, milliunits/minute",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosage interval, minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low-dose",
"       </td>",
"       <td>",
"        0.5 to 1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        30 to 40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alternative low-dose",
"       </td>",
"       <td>",
"        1 to 2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        15 to 30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        High-dose",
"       </td>",
"       <td rowspan=\"2\">",
"        6",
"       </td>",
"       <td>",
"        6 &nbsp;The incremental increase should be reduced to 3 milliunits/minute if hyperstimulation is present, and reduced to 1 milliunit/minute if recurrent hyperstimulation.",
"       </td>",
"       <td rowspan=\"2\">",
"        15 to 40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Some clinicians limit to a maximum cumulative dose of 10 units and a maximum duration of 6 hours.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Alternative high-dose",
"       </td>",
"       <td rowspan=\"2\">",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td rowspan=\"2\">",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Oxytocin should be administered by trained personnel who are familiar with its effects.&nbsp;It should be administered using an infusion pump that provides precise flow rate to ensure accurate minute to minute control. Most clinicians&nbsp;will not administer more than 40 milliunits/minute as the maximum dose.&nbsp;",
"    </p>",
"    <div class=\"footnotes\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"     Sample oxytocin infusion protocols courtesy of author with additional information from ACOG Committee on Practice Bulletins - Obstetrics, ACOG Practice Bulletin No.107: Induction of Labor. Obstet Gynecol 2009; 114:386.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_3_1084=[""].join("\n");
var outline_f1_3_1084=null;
var title_f1_3_1085="Cellular patterns in BAL";
var content_f1_3_1085=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Bronchoalveolar lavage: common cellular patterns in selected diseases",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Lymph",
"      </td>",
"      <td class=\"subtitle1\">",
"       Neutro",
"      </td>",
"      <td class=\"subtitle1\">",
"       Eosino",
"      </td>",
"      <td class=\"subtitle1\">",
"       Mast cells",
"      </td>",
"      <td class=\"subtitle1\">",
"       Other features",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\" rowspan=\"1\">",
"       Inflammatory diseases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       IPF",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       N",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       PF-CTD",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       N",
"      </td>",
"      <td>",
"       Increased lymphocytes in early disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Cryptogenic organizing pneumonia",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +/-",
"      </td>",
"      <td>",
"       Foamy macrophages; mixed pattern of increased cells characteristic; decreased CD4:CD8 ratio",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Eosinophilic pneumonia",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       N",
"      </td>",
"      <td>",
"       ++++",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Asbestosis",
"      </td>",
"      <td>",
"       N",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       N",
"      </td>",
"      <td>",
"       Ferruginous bodies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Silica-exposed",
"      </td>",
"      <td>",
"       +/-",
"      </td>",
"      <td>",
"       N",
"      </td>",
"      <td>",
"       N",
"      </td>",
"      <td>",
"       N",
"      </td>",
"      <td>",
"       Dust particles by polarized light microscopy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Coal workers' pneumoconiosis",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       N",
"      </td>",
"      <td>",
"       N",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Aluminum potroom workers",
"      </td>",
"      <td>",
"       N",
"      </td>",
"      <td>",
"       N",
"      </td>",
"      <td>",
"       N",
"      </td>",
"      <td>",
"       ?",
"      </td>",
"      <td>",
"       + LTT",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\" rowspan=\"1\">",
"       Granulomatous diseases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sarcoidosis",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"      <td>",
"       N or +",
"      </td>",
"      <td>",
"       N",
"      </td>",
"      <td>",
"       N",
"      </td>",
"      <td>",
"       CD4/CD8 &ge;2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hypersensitivity pneumonitis",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       N or +",
"      </td>",
"      <td>",
"       N",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       CD4/CD8 &lt;1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Chronic beryllium disease",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       N or +",
"      </td>",
"      <td>",
"       N",
"      </td>",
"      <td>",
"       N",
"      </td>",
"      <td>",
"       + LTT to beryllium salts",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     +: increase; N: normal values; lymph: lymphocytes; neutro: neutrophils; eosino: eosinophils; IPF: idiopathic pulmonary fibrosis; PF-CTD: pulmonary fibrosis associated with connective tissue disease; LTT: lymphocyte transformation test.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_3_1085=[""].join("\n");
var outline_f1_3_1085=null;
var title_f1_3_1086="Decline post transfusion HCV";
var content_f1_3_1086=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 494px\">",
"   <div class=\"ttl\">",
"    Incidence of posttransfusion hepatitis C",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 474px; height: 259px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Source: Centers for Disease Control and Prevention.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: MJ Alter, Tobler LH, Busch MP. Clin Chem 1997.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_3_1086=[""].join("\n");
var outline_f1_3_1086=null;
var title_f1_3_1087="Impetigo pustules PI";
var content_f1_3_1087=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F72412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F72412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skin sores caused by impetigo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 322px; height: 213px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sometimes impetigo causes red-rimmed, painful sores on the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Larry M Baddour, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_3_1087=[""].join("\n");
var outline_f1_3_1087=null;
